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1Chapter 1: Introduction
Cells are the fundamental units of life that contain all the working machinery nec-
essary for their functioning, survival, and death. This working machinery involves
proteins, in general, and RNAs, in some cases. The process through which life gener-
ates this working machinery is known as gene expression. Typically, in a eukaryotic
cell nucleus, parts of DNA that constitute an expressing gene are transcribed into a
(messenger) RNA. The messenger RNA then gets translated into a protein, which in
turn usually goes through post-translation modification before becoming a functional
part of the cell. These proteins participate in virtually all functions within the cells. In
non-protein coding RNA genes, transcribed genes encode for functional RNAs such as
ribosomal RNA and transfer RNA, or long non-coding RNAs. These RNAs participate
in a protein-assembly process, chemical (e.g. catalytic) activities, and chromosomal
inactivation [Lee, 2009] as well as genes regulation [Mercer et al., 2008].
Various genes are expressed or silenced in different cells and tissues, or under
different stimuli, internal or external to the organism. A change in the expression
patterns of particular genes may give rise to a phenotype [Alberts et al., 2003], cause
a disease [Dermitzakis, 2008], or even decide about the fate of the cell [Brand and
Perrimon, 1993]. Such changes may be caused by mutagens, hormones, or the ad-
dition or removal of epigenetic tags such as ethyl or methyl groups. Understanding
the structure and attribute of genes and the proteins they encode holds the promise
of enabling us to understand disease states in a fundamental way that was not avail-
able before the rapid sequencing of genes and genomes that is now available. High
throughput technologies like DNA microarrays enable us to measure the gene expres-
sion patterns on genomic scale. Typically, gene expression levels are measured in the
observed biological condition or tissue and compared with the expression patterns in
normal. Genes that are expressed differentially according to some rules or criteria are
2known as differentially expressed (DE) genes. The measurement of such expression
levels is only a starting point in the desired direction. The correct and efficient biolog-
ical interpretation of the voluminous data generated by these technologies, however,
remains a challenging problem. A commonly used approach in interpreting the results
of such high throughput experiments is to map the list of differentially expressed genes
to gene ontology (GO) terms [Khatri et al., 2002, Dra˘ghici et al., 2003, Rhee et al.,
2008] that provides a list of biological processes, biochemical functions, and cellular
locations associated with the DE genes. A previously unexplored aspect is the identi-
fications of unusual associations between biological processes. Such associations may
be signaling biological processes that interact in a specific way in the condition under
study.
Here we present a novel approach that aims at identifying such associations between
biological processes, which display a phenotype that is significantly different from
the norm. In brief, we develop a vector space model of the functional categories
annotated with the differentially expressed genes related to a phenotype. Next, we
compute the strengths of association among functional categories and compare those
with the corresponding association strengths in the absence of such phenotype. We
then identify pairs of biological functions whose association strengths have significantly
changed in the phenotype. We used our approach on real data sets involving breast
and lung cancer, and predicted associations among biological processes of the GO
ontology that were annotated with differentially expressed genes. More than 89% of
the predicted associations were found to be correct and valid by an extensive manual
review of literature. A subset of such interactions are discussed in details, in chapter 8,
and shown to have the potential to open a number of new avenues for research in lung
and breast cancer. These results indicate that the idea of expanding our interpretation
efforts beyond a single processes may be useful in understanding specific experiments.
31.1 Dissertation outline
The dissertation is divided into nine chapters and two appendices. Chapter 2,
biological foundations, begins with the definition of some fundamental terms and con-
cepts that are essential to the central dogma of molecular biology - the expression of
genetic information flows from DNA to RNA to proteins. The chapter then proceeds
to briefly describe current gene expression measurement technologies, before explain-
ing the GO - one of the most popular vocabularies used for genes annotation, and
its structure. The chapter concludes by explaining how gene expression is used by
researchers to understand the biological phenomenon under study.
Chapter 3, mathematical foundations, outlines the methods and models from the
fields of mathematics (linear algebra) and information retrieval systems, which creates
a base for the data model relevant to this work and presented in chapter 4. This
chapter explains how data can be represented as vectors and projected to spaces
with lower dimensions for noise reduction and for building the higher concepts in the
latent semantic space. Towards the end, the statistical correlation is geometrically
interpreted.
Chapter 4, identifying interactions between biological processes, outlines the defin-
ing aspects of our research approach. This chapter describes the research methodol-
ogy, in details, involving data representation, reduction of data in subspaces of lower
dimensions, association of biological processes and prediction of interactions using
parametric hypothesis testing.
Resemblance of our data model to the one used in IR incited us to try alterna-
tive weighting schemes. These weighting schemes have been presented in chapter 5,
improvements and enhancements. Algorithmic details of model implementation are
discussed in chapter 6, implementation details.
Chapter 7, literature review, focuses on the related work and the methods used
for the interpretation of the gene expression data and discusses their advantages and
4disadvantages; thus making the case for our proposed model.
In chapter 8, results and discussion, we evaluate and discuss a selected set of
predicted functional interactions between biological processes in the light of extensive
literature review. Chapter 9, conclusions and future directions, concludes our work,
summarizes the results, and suggests possible future directions that our research may
lead to.
Appendices A and B list all the results in tabular format for the breast and lung
cancer data sets, respectively, predicted by our methods. The description of columns
is presented at the beginning of each appendix.
5Chapter 2: Biological foundations
The basic functional unit of life is the cell [Alberts et al., 2003]. The cell contains
all the information that is necessary for its functioning and reproduction in the form of
genetic material. In most organisms, this genetic material exists as deoxyribonucleic
acid (DNA). For more evolved organisms, called eukaryotes, the DNA is contained in
a subpart of a cell called nucleus. For more primitive organism, called prokaryotes,
the DNA is found in the cytoplasm. Viruses also contain DNA or (in the case of
retroviruses) ribonucleic acid (RNA), but not both [Black, 1999]. However, viruses
have the ability to neither function, nor reproduce in the absence of a host and hence
it is unclear if they should be considered alive or not [Luria and Darnell, 1967, Bandea,
1983, Hendrix et al., 2003, Forterre, 2006, Claverie, 2006]. Unlike the cells of more
evolved life forms, they do not contain nucleus, nor cytoplasm and rely on host cells
for replication.
Higher organisms, such as humans, are vast colonies of very specialized cells, almost
all of which contain virtually exact copy of the same genetic material. However,
differential gene expression leads to the different properties of the tissues, and then
the different processes which characterize the different tissues. Cells differentially
express various genes as a consequence of internal or external stimuli [Alberts et al.,
2003]. Researchers observe these gene patterns and try to understand the stimuli that
caused the measured gene expression.
In the next section, we will explain some of the concepts necessary to understand
the gene expression mechanism as well as the molecules that participate in it. Further-
more, we will briefly describe the gene expression mechanism itself. The remainder of
the chapter contains a description of some of the current technologies used to mea-
sure gene expression levels. We also explain how the current knowledge about genes
is stored in the gene ontology (GO) database and how we can use it to understand
6expressed genes and the corresponding biological functions.
2.1 DNA, RNA, and proteins
DNA - deoxyribonucleic acid, contains all the information necessary for the func-
tioning of a cell. DNA is a threadlike molecule made up of a double chain of nu-
cleotides. Nucleotides are the chemical compounds that are distinguished based upon
the four bases they contain. These bases are abbreviated A for adenine, C for cyto-
sine, G for guanine, and T for thymine, for convenience. These bases make hydrogen
bonds with each other such that A pairs with T and C pairs with G. It is due to this
complementary base pairing that the two strands of complementary nucleotide chains
bond together to form the double helical structure of a DNA [Watson and Crick, 1953]
as shown in Figure 2.1. Sugars and phosphate groups make the backbone of this DNA.
For convenience, nucleotides chain and base pairing is described in linear format as
Figure 2.2.
In eukaryotes, this long DNA is packaged into a set of chromosomes. In humans,
for example, approximately three billion nucleotide pairs are grouped into 23 chromo-
somes. These chromosomes are found in pairs - each chromosome in a pair comes from
one of the parents. Chromosomes in any one of the 22 pairs contain related genetic
material and are called homologs. However, chromosomes in the 23rd pair in males
are not homologs - one of them is called X and the other Y. X chromosome is inherited
from the maternal side, while the Y chromosome comes from the paternal side. In
prokaryotes, DNA is usually found as a single circular molecule.
RNA - ribonucleic acid, is a single stranded molecule of nucleotides chain. This
chain is also made up of four bases - A, C, G, and U. Here, A, C, and G represent the
same bases as in the DNA, however, U replaces T and represents the base uracil. In
RNA, C can bond with G and A can bond with U (uracil), as apposed to a T in the
DNA. A linear structure of RNA is illustrated in Figure 2.3.
7Adenine
Thymine
Guanine
Cytosine
Sugar-phosphate
backbone
Base  pair
Figure 2.1: Double helical structure of DNA and complementary base pairing - base
A (adenine) pairs with base T (thymine) and C (cytosine) with G (guanine). DNA
backbone is made of alternating sugar and phosphate groups. Image adapted from
wiki commons.
8· · · G T G C A T · · ·
| | | | | |
· · · C A C G T A · · ·
Figure 2.2: DNA linear structure and complementary base pairing - A (adenine) pairs
with T (thymine) and C (cytosine) pairs with G (guanine).
· · · G U G C A U · · ·
Figure 2.3: RNA linear structure consisting of A (adenine), C (cytosine), G (guanine),
and U (uracil) bases.
Each triplet of nucleotides in an RNA corresponds to an amino acid. There are 20
types of amino acids in humans, and more than one triplets of nucleotides can map
to the same amino acid. These amino acids can bond together during gene expres-
sion mechanism to form polypeptide chains. This is explained in the next section.
Proteins are the chains of these polypeptides and usually posses three dimensional
structures. Proteins are involved in almost all functions in a cell. When heated to a
certain temperature, proteins loose their structures and nucleotide bonds break, in a
process called denaturing.
Figure 2.4 explains the linear structure of a protein. Here, V stands for valine, H
for histidine, and L for leucine, etc. and represent the amino acids. Although amino
acids are known by the acronyms of their own, alternatively they are known by the
corresponding triplets on RNA, as well.
· · · V H L T P E · · ·
Figure 2.4: Linear structure of a protein containing chains of amino acids - valine (V),
histidine (H), leucine (L), etc.
9Figure 2.5: RNA Transcription. RNA polymerase (RNAP) reads one strand of the
DNA starting at specific spot, and constructs RNA based upon complementary base
pairing rule. Image adapted from wiki commons.
C C A G T A C G · · · ssDNA
| | | |
| | | |
| | | G U A C | · · · RNA
G G T C A T G C · · · ssDNA
Figure 2.6: RNA is transcribed using complementary base-paring rule.
2.2 Gene expression
Under certain circumstances, two strands of DNA separate locally. A molecular
machinery - RNA polymerase, reads the nucleotide sequence on one strand and creates
a chain of complementary nucleotides - pairing T on DNA with A, C with G, G with
C, and A with U. This process continues until the RNA molecule is completed. The
synthesized RNA molecule is also known as a transcript. Transcription is a process
that makes transcripts and is illustrated in Figures 2.5 and 2.6.
Occasionally, some parts of RNA, called introns, are cut out and disposed off. The
remaining parts, called exons, are spliced together to form what is called amessenger
RNA or mRNA. RNA splicing is shown in Figures 2.7 and 2.8.
The mRNA then moves to the cytoplasm out of the nucleus and is processed
further on a workbench, called ribosome. Each nucleotide triplet on mRNA, called
a codon, is read and is paired with the complementary triplet of nucleotides on the
transfer RNA (tRNA), freely moving in the cytoplasm. Each tRNA carries one of
10
pre-mRNA
mRNA
Exon Intron Exon Intron Exon
Figure 2.7: RNA splicing. Introns - parts of RNA, are cut-out and disposed off; exons
- other parts of RNA, are spliced together to form mRNA. Image adapted from wiki
commons.
G U A C · · · G U A A · · · transcribed RNA
× × × × · · · cut out introns (×)
U A C U A · · · joined exons (mRNA)
Figure 2.8: RNA splicing - linear representation. Introns, marked by X, are cut out
and exons are joined together.
the 20 amino-acids. As various amino acids are brought together with tRNAs having
complementary triplets to the codons on the mRNA, they join together using peptide
bonds and form a linear chain of amino-acids. During this process, called translation,
the information carried by mRNA gets translated to a specific chain of amino-acids
in the synthesized protein. The process of translation is illustrated in Figure 2.9. The
linear chain of amino-acids then go under post translational modifications. Finally,
the protein gets transported to an area of cell where it is supposed to perform its
function.
The central dogma of molecular biology - the flow of genetic information from
DNA to RNA (in transcription) and from RNA to proteins (in translation) during the
process called gene expression, is illustrated in Figure 2.10. The process of gene
expression is very complex in real life; however, the simplified version described above
will suffice to understand the related parts of this dissertation. The total information
of genes on all chromosomes is termed as genome.
11
Figure 2.9: Protein translation. Ribosome reads mRNA with three nucleotides at
a time and matches with a complementary tRNA. Corresponding amino acids form
peptide bonds to make the protein. Image adapted from wiki commons.
GTGCATCTGACTCCTGAGGAGAAG
CACGTAGACTGAGGACTCCTCTTC
GUGCAUCUGACUCCUGAGGAGAAG
V H L T P E E K
DNA
(transcription)
RNA
(translation)
protein
. . .
. . .
. . .
. . .
. . .
. . .
. . .. . .
. . .
Figure 2.10: Gene expression. Nucleotide bases in DNA are transcribed into comple-
mentary bases of mRNA. Nucleotides in mRNA are translated into amino acids based
upon triplets of nucleotides in the mRNA. Image adapted from wiki commons.
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In non-protein coding RNA genes, transcribed genes encode for functional RNAs
such as ribosomal RNA (rRNA), transfer RNA (tRNA), and long non-coding RNA
(ncRNA). Ribosomal and transfer RNAs participate in a protein-assembly processes
or other chemical (e.g. catalytic) activities. Long ncRNAs are hypothesized to partici-
pate in chromosomal inactivation [Lee, 2009] and gene regulation [Mercer et al., 2008].
The end result of gene expression process, whether it be a protein or a functional
RNA, is called a gene product.
2.3 Gene expression measurement technologies
Gene products, most of which are proteins, are the functional machinery of cells.
Ideally, gene expression level should be measured by the amount of synthesized pro-
teins. However, for practical reasons, the amount of mRNA is considered to be a good
measure of gene expression. Various methods that analyze gene expression levels
include, but not limited to northern blotting [Alwine et al., 1977] through gel elec-
trophoresis, quantitative polymerase chain reaction (qPCR or QRT-PCR, or simply
PCR)[VanGuilder et al., 2008, Becker-Andre and Hahlbrock, 1989] through comple-
mentary DNA (cDNA) amplification and detection, serial analysis of gene expression
(SAGE)[Velculescu et al., 1995] through sequence tags, and DNA microarrays [Schena
et al., 1995, Brazma and Vilo, 2000] through probe hybridization, etc. Each of these
technologies is briefly described here.
Northern blotting
In northern blotting, isolated RNA samples are placed in gel and spatially sep-
arated using electrophoresis based upon different RNA sizes. A filter and blotting
papers are put on top of the gel and weight is applied. RNA moves to the filter
by the capillary action. The filter is separated and treated with radioactive single
stranded DNA (ssDNA) probes. Probes are sequences of RNA (or ssDNA) and used
13
Figure 2.11: Northern blotting. After electrophoresis, gel contains the spatially sepa-
rated RNAs. A filter and blotting papers are put on top of the gel and weight applied.
RNAs in gel move to the filter due to capillary action.
to detect the presence of complementary (target) sequences through base-pair bond-
ing. Hybridized probes are detected using X-ray. By looking at the differences in
the quantity of mRNA expression in different biological conditions, researchers try
to either determine the functionality of unknown proteins, or gain information about
cellular responses in the studied condition.
The term ’blot’ comes from the fact that RNA is transfered, during the process,
from electrophoresis gel to the blotting membrane. The word ’northern’ comes as a
contrast to the word Southern in the Southern blot mechanism, invented by Edwin
Southern [Southern, 1975]. In Southern blotting, DNA fragments are used instead of
RNA. However, the term ’northern’ does not come from any scientist named Northern.
Figure 2.11 illustrates this blotting mechanism. Although easy to use, this mechanism
is slow and not designed to simultaneously measure expression of many genes. The
radioactive material used poses additional risks although non-radioactive methods
have been proposed [Shifman and Stein, 1995, Solanas et al., 2001].
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Quantitative (real time) polymerase chain reaction
When the amount of mRNA to be measured is short, complementary DNA or
cDNA are transcribed using DNA polymerase. The method is called reverse tran-
scription (RT) and is also employed by the RNA viruses. DNA is then amplified us-
ing polymerase chain reaction (PCR) [Saiki et al., 1985, Bartlett and Stirling, 2003].
PCR is a method wherein DNA is repetitively heated and cooled along with reagents
and enzymes to generate thousands to millions of replicas of desired DNA fragment.
Heating causes strands of DNA to denature (separate). In the presence of reagents
and enzymes, and appropriate temperature, the process of DNA synthesis begins and
complementary DNA strands are formed. The two steps in the procedure are called
annealing and elongation, respectively. The procedure is illustrated in Figure 2.12.
During each cycle of heating and cooling, DNA dyes or fluorescent reporter probes
are added to the solution at appropriate time. DNA dyes bound to double stranded
DNAs and fluorescent reporter probes hybridize at specific sequences of DNA. The
intensity of fluorescence is measured in various samples and quantified as relative gene
expression.
This method is a low throughput technology; however, it does not allow precise
quantification of gene expression. It also poses increased risk of false negatives [Klein,
2002].
Serial analysis of gene expression
Serial analysis of gene expression (SAGE) is one of the high throughput technolo-
gies. In this technique, small portions of sequences (tags) from input sample mRNAs
are extracted and linked together into a long chain. The small sequence tags are
counted after the cloning and sequencing of long chains. The number of counts along
with tags is used to estimate the proportion of mRNA (and hence the gene) from
which the tag was extracted [Velculescu et al., 1995]. SAGE has been illustrated in
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Figure 2.12: Polymerase chain reaction. From top to bottom: the procedure begins
with denaturation of cDNA, and during the annealing and elongation steps the DNA
synthesis begins, and complementary strands of DNA are synthesized, respectively.
Image adapted from wiki commons.
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Figure 2.13.
This technology is very expensive, hence large-scale studies generally do not use
SAGE.
Microarrays
Microarrays are small structures of glass, plastic, or nylon membrane on which
parts of ssDNA with know sequences are deposited in an array- (grid-) like patterns.
The microarray is washed by the solution containing (single stranded) ssDNA from
the samples under investigation. These ssDNAs are synthesized from tissues through
reverse transcription. The hybridized amount of DNA is considered to be a good
measure of the mRNA expression in the sample tissue. Usually, the amount of hy-
bridization is also measured for mRNAs in normal tissue and the two measurements
compared. Genes containing hybridized DNAs with significant varying quantities in
the two conditions are considered to be differentially expressed. Since an array can
be manufactured with DNA sequences from thousands of different genes, a single ex-
periment can produce expression measurements for a large amount of genes [DeRisi
et al., 1997, Brazma et al., 2001]. The hybridization is illustrated in Figure 2.14.
Any of these technologies can have an advantage over the other. For example,
at times northern blotting is able to detect small changes in gene expression that
microarrays cannot [Taniguchi et al., 2001]. However, this technique is good for an-
alyzing one gene at a time. RT-PCR is usually employed after the identification of
a transcript by northern blot mechanism to amplify the cDNA for a more detailed
study on the related gene. Diagnostic real-time PCR is applied to rapidly detect nu-
cleic acids that are diagnostic of, for example, infectious diseases, cancer and genetic
abnormalities [Sails, 2009]. Despite their initial popularity, this technology is suited
for the analysis of only a small number of genes. Most studies involving gene expres-
sion analysis on genomic scale use microarrays as a preferred method. SAGE is also a
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Figure 2.13: Serial analysis of gene expression (SAGE). Small portions of sequences
(tags) from input sample mRNAs are extracted and linked together into a long chain.
Analysis of cloned long chains provides measure of expression. Image adapted from
www.sagenet.org.
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Figure 2.14: DNA hybridization of the target on microarray probes. Targets are
fluorescently labeled. Targets containinting complementary bases to the probes bind
strongly. Weakly bound targets are washed away. The fluorescent intensity of a spot on
the microarray, containing specific probes, represents the measure of gene expression
corresponding to the probe. Image adapted from wiki commons.
high throughput technology with equal quantitative accuracy [Ishii et al., 2000, Kim,
2003]; however, it is expensive compared to microarrays.
2.4 Gene Ontology
DNA microarrays produce gene expression measurements on genomic scale, re-
searchers face the challenge of analyzing the set of differentially expressed genes. Exist-
ing knowledge about differentially expressed genes plays an important role. Currently,
the functional information about genes is stored in annotation databases employing
well-defined ontologies like GO [Ashburner et al., 2000].
The gene ontology (GO) project provides three parallel ontologies - cellular compo-
nents, molecular functions, and biological processes. These ontologies are structured
in the form of directed acyclic graphs (DAGs). Each GO term in the DAG is rep-
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Figure 2.15: Gene Ontology (sub) graph representation of the M phase of meiotic cell
cycle and cytokinesis. Image adapted from www.yeastgenome.org/help/GO.html.
resented by a node. An edge between two nodes represents a child-parent relation
wherein a biological function represented by one node can either be an ’is-a’, or a
’part-of’ another function represented by the other node. An ’is-a’ relationship means
that the child is a subtype of its parent, while a child node in a ’part-of’ relationship
shows that it is a component of the parent in that relation. ’Regulates’ is a third
type of relation wherein a child always regulates its parent; however, a parent may not
always be regulated by the child. A node in a DAG can have more than one parent.
A subset of GO is illustrated in Figure2.15.
Terms associated with nodes at the lower level of the graph define more specific
biological functions than their ancestors. GO term associated with a node at the root
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level defines the biological function in the most generic sense. Genes are annotated
with GO terms based upon the most specific activity the synthesized gene product
participates in. However, it is because of the parent-child relationship, a gene anno-
tated to a specific term in the graph is implicitly assumed to be annotated with all
the parent nodes, as well.
In the rest of this dissertation we will focus on identifying significant relationships
between biological processes. However, the method we developed can be equally well
deployed to identify relationships between any type of GO category. Furthermore, the
same approach can also be used on any type of ontology.
2.5 Phenotype and genotype
Although all individuals in a species share the same genetic material, small individ-
ual variations exist. When the same region of genome is compared between two human
individuals, they differ at only 1 in 1000 nucleotides. It means any two individuals
resemble 99.9% with respect to their genetic material [Kruglyak and Nickerson, 2001].
This apparently small variation becomes significant when accumulated over the entire
set of 3.2 billion base pairs in an individual. This variation is the result of mutations
in the DNA of the X and Y chromosomes inherited from the parents and accumulated
over evolutionary time period. The genetic constituent of an organism is called its
genotype, and the genotype’s physical expression is called the phenotype [Black,
1999]. For example, in humans, some of the individual variations can easily be ob-
served (e.g. eye color), while others can be detected (e.g. blood type group) with tests
and experiments.
Mutations are the changes in the nucleotide sequence of a DNA. For example, a base
pair might get deleted, inserted, or replaced with a different one in the DNA sequence.
These changes can occur due to the presence of various factors including radiations,
viruses, and some chemical compounds. These mutation causing factors are termed
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as mutagens. The mutations caused by the mutagens are called induced mutations.
Spontaneous mutations can also occur, in the absence of mutagens, due to errors in
the DNA replication during a cell division. Such changes in the DNA sequences can
modify the synthesized gene product with an altered or silenced functionality. Cells
can also modify gene expression due to internal or external stimuli. These changes,
whether due to gene expression levels or in the presence of mutagens, may give rise to
a phenotype [Alberts et al., 2003], cause a disease [Dermitzakis, 2008], or even decide
about the fate of the cell [Brand and Perrimon, 1993].
Working backward from the phenotypes - e.g. the observed characteristics in the
cancer and other diseases, researchers perform experiments and try to understand the
underlying genotype. They use the above described technologies and determine which
genes are expressed differentially in the given phenotype. Using this information, life
scientists try to understand the underlying biological mechanism that gave rise to such
phenotype. In the next section, we will briefly describe how current methods try to
achieve this goal using differential gene expression data.
2.6 Identifying the biological phenomena - current approaches
GO annotation databases are being continually updated so that they contain com-
prehensive summaries of the functional information known from previous biological
experiments. Thus, new experimental results and information can be readily ana-
lyzed and integrated. Researchers extract functional profiles of the expressed genes to
develop an insight about the biological phenomena under study.
An approach based on the identification of the biological processes that are signifi-
cantly over- or under-represented in the set of DE genes is the most widely used for this
purpose [Rhee et al., 2008]. The first step in methods following this approach involves
the selection of the differentially expressed genes, between a given condition versus nor-
mal. The selection is made based on statistical tests such as the t-test with a chosen
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Biological functions DE genes
mitosis 160
oncogenesis 80
positive regulation of cell proliferation 60
glucose transport 40
Table 2.1: Representation of the functional categories for the differentially expressed
genes in a microarray experiment - an example.
significance level (usually, p ≤ .05) and an arbitrary fold change (≥ 1.5 or 2) [Huang
et al., 2009]. Next, the number of differentially expressed genes found in each GO
category of interest are compared with the number of genes expected to be found in
the same category just by chance. If the observed number is substantially different
from the one expected just by chance, the category is reported as significant.
Assume that we are investigating an effect of ingesting a certain substance X [Dra˘ghici,
2003, Chapter 14]. Suppose an experiment using microarray, containing 2000 genes,
report 200 genes to be differentially regulated. Let us further assume that the results
of the 200 DE genes are as follows: 160 of the 200 genes are involved in mitosis, 80
in oncogenesis, 60 in the positive regulation of cell proliferation, and 40 in glucose
transport (see Table 2.1).
Mitosis is a process comprising the steps by which the nucleus of a eukaryotic cell
divides, which results in the two daughter nuclei whose chromosome complement is
identical to that of the mother cell; whereas the positive regulation of cell prolifera-
tion term represents any process that activates or increases the rate or extent of cell
multiplication or reproduction. Glucose transport is a process involving the directed
movement of the hexose monosaccharide glucose into, out of, within or between cells
by means of some external agent such as a transporter or pore.
By looking at the above table, one is tempted to assume that the top three processes
are the most significant, and substance X may be related to cancer. However, if the
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Biological processes DE genes Expected genes
mitosis 160 160
oncogenesis 80 80
positive regulation of cell proliferation 60 20
glucose transport 40 10
Table 2.2: Correct representation of the functional categories for the differentially
expressed genes in a microarray experiment - an example.
used microarray contained genes most of which were on a mitotic pathway, then the
relevance of cancer does not remain significant. Consider for example the occurrences
of expected genes for each individual category as in Table 2.2.
In the light of this new information, mitosis and oncogenesis do not remain signif-
icant. Although these functions are expressed in high quantity, but this high quantity
was already expected due to the presence of high number of genes related to mitosis
and oncogenesis. Genes related to positive regulation of cell proliferation are expressed
three times more than our expectation, and genes related to glucose transport are ex-
pressed four times more than our expectation. Hence, substance X seems to be related
to diabetes instead of cancer. This example illustrates the fact that taking into con-
sideration the expected numbers of gene dramatically changes the interpretation of
gene expression data.
In this chapter we focused on the biological foundations necessary to grasp our
work in perspective. In the next chapter, we focus on mathematical concepts that will
be later used in describing our research methodology.
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Chapter 3: Mathematical foundations
The field of bioinformatics focuses on using information technology and computer
science methods and algorithms to solve problems in life sciences. The success of
information retrieval techniques, like latent semantic indexing (LSI) devised after the
advent of modern computational devices, has encouraged researchers to incorporate
these methods in areas other than the information systems. We will first focus on
representing and processing the information contained in a document collection and
then build our model based on these techniques to gain insight into the biological
information.
3.1 Vector space model
A typical problem in the information retrieval (IR) systems is the search of rele-
vant documents in a vast collection of documents, based on query terms. Traditional
methods in early automated IR systems used keywords to search indexes created by
automated text processing techniques. However, these automated methods suffered
from two fundamental problems: polysemy and synonymy. Natural languages are
complex, and a word can have different meaning under different contexts (polysemy)
and different words can represent the same idea (synonymy). A user may use synony-
mous or polysemous words to mean the same or different concepts in the query. For
example, a user may use the word auto instead of vehicle, or use the word bank to
mean river bank and not the memory bank in a computer. In general, automated text
processing methods are not robust enough to deal with such issues.
3.1.1 Data representation
Early research in this area [Luhn, 1957, Salton and McGill, 1983] suggested repre-
senting documents as vectors of keywords extracted from the document. Each compo-
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nent of a vector represents the importance of a keyword or concept to the document
represented by the vector. All the vectors in a collection of documents are represented
as the columns of a matrix, say A. For example, a collection of d documents containing
t terms can be described using equation 3.1.
At×d =


a11 a12 . . . a1d
a21 a22 . . . a2d
...
...
. . .
...
at1 at2 . . . atd


(3.1)
The same matrix can also be written as:
At×d = (D1 D2 · · ·Dj · · ·Dd) (3.2)
where Dj = (a1j a2j · · ·atj)T is t-dimensional vector that describes the document
j. The component aij, for some i = 1 · · · t and j = 1 · · · d, is assigned a value (weight)
based upon the importance of term i in document j. In the simplest weighting assign-
ment, it is 1 if the term i appears in document j, or 0 otherwise.
At×d = {aij} =


1 if term i is found in
document j
0 otherwise
(3.3)
Similarly, a query against this collection can be represented by the following vector
Q, where qi, for i = 1 · · · t represents the importance of term i for the query.
Q = (q1 q2 · · · qt)T (3.4)
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3.1.2 Information retrieval
Once the information has been represented as vectors, we can exploit the geomet-
rical interpretation of similarities or differences between a query vector and vectors in
the collection A, or between vectors within A. Documents most relevant to the query
would be the vectors geometrically closest to the query vector according to some mea-
surement rules. One such commonly used measure is the cosine similarity [Salton and
McGill, 1983]. Cosine similarity is defined as the dot product between two vectors,
and usually normalized by their lengths. For example, the cosine similarity between
the query vector Q and document vector Dj is defined as:
similarity (Q,Dj) =
QT ·Dj
‖ Q ‖ · ‖ Dj ‖ (3.5)
where
QT ·Dj =
t∑
i=1
qi · aij = q1 · a1j + q2 · a2j + · · ·+ qt · atj (3.6)
and
‖ Q ‖=
√
QT ·Q =
√√√√ t∑
i=1
q2i =
√
q21 + q
2
2 + · · ·+ q2t (3.7)
‖ Dj ‖=
√
DTj ·Dj =
√√√√ t∑
i=1
a2ij =
√
a21j + a
2
2j + · · ·+ a2tj (3.8)
The similarity measurement represents the cosine of the angle between the two
vectors. A higher value of this measure implies that the two vectors are close to each
other in the space of terms. This would mean that the documents representing these
vectors are relevant. A threshold value is used to select the related documents.
Consider, for example, the set of five documents shown in Table 3.1 [Berry et al.,
1999]. Further suppose that we pick the italicized terms from the document collection
above, in the order shown in Table 3.2.
27
Document collection
D1: How to bake bread without recipes
D2: The classic art of Viennese pastry
D3: Numerical recipes: the art of scientific computing
D4: Breads, pastries, pies and cakes : quality baking recipes
D5: Pastry : a book of best French recipes
Table 3.1: A collection of five documents. Table reproduced from [Berry et al., 1999]
Terms
T1 : bak(e,ing)
T2 : recipes
T3 : bread
T4 : cake
T5 : pastr(y,ies)
T6 : pie
Table 3.2: A set of six keywords chosen from the set of five documents in Table 3.1.
A 6 × 5 term by document matrix describing the above collection and keywords
can be constructed as:
At×d = A6×5 =


1 0 0 1 0
1 0 1 1 1
1 0 0 1 0
0 0 0 1 0
0 1 0 1 1
0 0 0 1 0


(3.9)
If a user requests books about baking bread, then the query vector can be written
as:
Q =
(
1 0 1 0 0 0
)T
(3.10)
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Applying cosine similarity measure, using equation 3.5, we get the following values:
1.15 for D1, 0.82 for D4, and 0 for D2, D3 and D5. If we select a cutoff value of 0.5,
documents D1 and D4 become relevant, as they ought to be.
Now, if a user requests books only about baking, the query vector becomes:
Q =
(
1 0 0 0 0 0
)T
(3.11)
The cosine similarity values returned by equation 3.5 are: 0.58 for D1, 0.41 for D4,
and 0 for D2, D3 and D5, as before. According to our chosen threshold value of 0.5,
D4 is no more relevant to our query, although it ought to be as in the previous case.
To resolve the problem, illustrated by the above example, a variety of approaches
have been proposed, such as by the use of controlled vocabulary [Kowalski, 1997], by
applying various weighting schemes [Salton and Buckley, 1988], and by approximating
the original term-document matrix by projecting it to a subspace of lower dimen-
sions [Deerwester et al., 1990, Berry et al., 1995]. In the following sections, we will
look at a couple of these weighting schemes, and then explain the concept of matrix
approximation.
3.1.3 Weighting schemes
Salton proposed and compared various weighting schemes for term by document
matrices [Salton et al., 1975, Salton and Buckley, 1988]. In general, the most common
weighting scheme applied to a term by document matrix assigns local and global
weights to the vector components based on the principle that the repeated terms in
a document are well suited to describe the topic of the document, while infrequent
terms across the document collection are suited to differentiate between documents.
As such, each component aij in A is considered to be a product of a local weight, term-
frequency and a global weight, inverse-document-frequency. Term frequency (tfij) is
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defined as the frequency of term ti in document j, and inverse-document-frequency
(idfi) is defined as the inverse of the proportion of documents containing the term ti
with respect to the entire collection. i.e.
aij = tfij · idfi (3.12)
where,
tfij =
frequency of term ti in document dj
sum of all the term-frequencies in document dj
(3.13)
and
idfi = ln
number of documents in the collection
number of documents containing the term ti
(3.14)
Here, term-frequency is normalized with the total number of terms in the document
to prevent bias towards longer documents (containing a lot of terms), and inverse-
document-frequency smoothed out by taking the log of it.
In a binary vector space model, the term-frequency (tfij) is assigned a value of
1 when a term ti appears, at least once, in document dj . Equation 3.13 modifies,
accordingly:
tfij =
1
number of terms in document dj
(3.15)
For a detailed study of various weighting schemes and their comparison, a paper
by Salton and Buckley [Salton and Buckley, 1988] is a good start.
3.1.4 Matrix approximation
By adopting the vector space model, one can readily apply the methods developed
in the area of linear algebra, and geometrically interpret the terms and document
collection in the represented vector space. For example, the subspace spanned by
matrix (document) column vectors is replaced with the subspace of lower dimensions.
Subsequently, an approximated matrix is computed [Deerwester et al., 1990, Berry
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et al., 1995, 1999] from this subspace of lower dimensions. In doing so, the underlying
assumption is that the subspace spanned by original column vectors does not represent
the true model of contents due to noise in the original data. The matrix approximation
tries to remove the noise and presents a subspace that is able to handle diverse queries
better.
Linearly independent vectors and matrix rank
A set of n vectors is considered linearly independent, if none of the vectors in the
set can be written as a linear combination of the other vectors in the set. Consider n
vectors {V1, V2, · · ·Vn} and the following equation:
a1V1 + a2V2 + · · ·+ anVn = 0 (3.16)
The n vectors are linearly independent only if scalars ai = 0 for all i = 1 · · ·n. If there
exist some non-zero ai that satisfy the above equation, then the set is not linearly
independent.
For example, consider the matrix A6×5 represented by equation 3.9. Vector in the
5-th column representing document D5 can be written as a combination of columns 2
and 3:
D5 = D2 +D3.
Hence, the vectors in that matrix are not linearly independent.
The maximal number of linearly independent rows (or columns) in a matrix, is
called the rank of that matrix.
Singular value decomposition
Given our t × d matrix A, representing the terms and documents in our collec-
tion, we can factorize it using singular value decomposition (SVD) into three matri-
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Figure 3.1: Singular value decomposition of a term by document matrix A. U and V
are orthonormal matrices. i.e. UUT = I, V TV = I, where I is the identity matrix; S
is a diagonal matrix of singular values si, such that s1 ≥ s2 . . . ≥ sr. The j-th column
of V T , D
′
j contains the coordinates of the j-th document in the coordinate system of
the scaled eigendocuments. Image adopted from [Wall et al., 2003].
ces [Golub and van Loan, 1983, Berry et al., 1999] - U , S, and V , such that:
At×d = Ut×r × Sr×r × V Tr×d (3.17)
where U and V are the matrices of left and right singular vectors, and S is the r × r
diagonal matrix of singular values, where r is the rank of A (i.e. the number of linearly
independent rows or columns). Graphically, the SVD is represented in Figure 3.1.
The diagonal values of matrix S have the property that s1 ≥ s2 . . . ≥ sr. In essence,
each singular value captures the amount of variability in the data along the direction of
the corresponding singular vector. Several of these singular values in the S matrix are
small and can be ignored without a significant loss of the features characterizing the
data. Usually, the first k largest singular values, corresponding to α% of the variance
in the data, are kept, and other singular values from k + 1 to r, are eliminated. The
value of k is the smallest of all k’s that satisfies the following inequality:
∑k
i=1 |si|∑r
i=1 |si|
≥ α
100
(3.18)
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Figure 3.2: Approximation of matrix in lower dimensional subspace. Ak is an approx-
imated matrix using only k singular values and corresponding columns and rows of U
and V T . The value aijk is an approximated value of original aij . Image adopted from
[Wall et al., 2003].
The columns and rows in the matrices U and V T corresponding to ignored singular
values are also eliminated as shown in Figure 3.2. This allows a projection of the
data in a lower-dimensional space without significant information loss. This reduced-
dimensionality matrix will be:
Ak = Uk × Sk × V Tk (3.19)
Note that this approximation captures the most important features of the data
without losing any term or document since the reduced term by document matrix Ak
has the same dimensions as that of the original term-document matrix. Here, the
subscript k is used to denote the fact that these matrices are those corresponding to
the first k singular values rather than to indicate the dimensionality of the matrix as
used in equation 3.17 and before.
Once the matrix A has been approximated, as described above, a similarity measure
can be used to find the related documents in the latent semantic space of terms and
documents. This technique has been successfully used in IR [Deerwester et al., 1990,
Berry et al., 1999], for microarray data analysis [Alter et al., 2000], and more recently
33
for the prediction of novel gene functions [Khatri et al., 2005a, Done et al., 2009].
3.2 Correlation and it’s geometric interpretation
Previously, we described how the documents related to a query can be retrieved
using the cosine similarity. This similarity measure can either be applied to vectors in
the original term-documents space or in the latent semantic space using an approxi-
mated matrix. Alternatively, statistical correlation also provides a method for finding
the relationship or association between a pair of data. Correlation is a measure of the
degree to which data from two (or more) samples vary.
In statistics, random variables, instead of vectors represent data points in a sample
because they are assumed to take any value from its domain defined for the sample.
We say that the two variables are correlated if both tend to simultaneously vary in
some direction, if represented in a Euclidean space. If both variables tend to increase
or decrease together, we say that the two variables are positively correlated. However,
when one variables decreases while the other increases, we say that the two variables
are negatively correlated. It should be noted here that the association between two
data sets can be linear or non-linear. Here, we will restrict the discussion to the idea
of linear correlation.
Numerical value of a linear correlation is known as a correlation coefficient. Usually,
the correlation coefficient is computed through a method proposed by Pearson [David,
1995, Seal, 1967]. If we denote the two variables describing the two sample data by X
and Y , with their mean values of X and Y , respectively, then the Pearson correlation
coefficient, rXY between X and Y , can be calculated as:
rXY =
σXY√
σXX · √σY Y =
∑
(X −X)(Y − Y )√∑
(X −X)2
√∑
(Y − Y )2
(3.20)
Here, σXY denotes a covariance between X and Y , while σXX or σ
2
X , and σY Y or
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Figure 3.3: Several sets of (X, Y) points, with the correlation coefficient of X and Y
for each set. Note that the correlation reflects the noisiness and direction of a linear
relationship (top row), but not the slope of that relationship (middle), nor many
aspects of nonlinear relationships (bottom). The figure in the center has a slope of 0
but in that case the correlation coefficient is undefined because the variance of Y is
zero. Image adapted from wiki commons.
σ2Y denote variances in X and Y , respectively.
An interesting observation can be made if we extrapolate the method of correlation-
coefficient computation to a vector space model. For example, by reconsidering X and
Y as vectors representing the samples with data values as components of the vectors,
equation 3.20 can be rewritten as:
rXY =
XTY√
XTX ·
√
Y TY
=
XTY
‖ X ‖ · ‖ Y ‖ (3.21)
Here, X and Y represent the vectors whose data values have been centered, i.e.
the mean of the values (of vector components) has been deducted from the original
component values. ‖ X ‖ and ‖ Y ‖ are called the norm of the vectors X and Y ,
respectively.
A comparison of the two equations, 3.5 and 3.21, reveals the similarities between
the two. It is evident that the correlation coefficient finds the cosine similarity between
vectors representing the data that has been centered.
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Obviously, the value of r varies between −1 and 1. Values closer to 1 and −1
indicate higher correlation (positive and negative, respectively); while values closer to
0 indicate less correlation. This measure of correlation is only linear and a value of 0
only indicates that the two variables are not linearly correlated, although they might
be non-linearly correlated. Figure 3.3 illustrates a few interesting and informative
cases of relationships between variable and their respective correlations.
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Chapter 4: Identifying interactions between
biological processes
In chapter 2, we learned how DNA microarray technology can produce gene ex-
pression measurements on a genomic scale. Also, we discussed how the gene ontology
can be used to store the gene annotations and yet the correct and efficient biological
interpretation of such expression measurements remains a challenging problem. The
discussion in chapter 3 has equipped us with the tools and techniques that we can
use as a foundation to erect a building of our research methodology, here. In this
chapter, we present our main contribution to the research of interpreting differentially
expressed genes data from DNA microarrays and the understanding of the underlying
biological mechanism using annotations to the biological processes from GO.
The technique described here aims to identify non-trivial relationships between
biological processes represented by GO terms that are statistically significant in a
given condition. The primary goal of this technique is to suggest novel hypotheses
and directions for further exploration of the condition under study. Any relationships
that can be directly inferred from the GO structure (e.g. a relationship between a
given GO term and any of its distant ancestors or descendants) are not considered
specific to the given condition and hence, are not reported.
In the work presented here we describe an approach that aims to: i) eliminate the
bias introduced by the presence of large information of extensively studied biological
processes or genes, and ii) extract any potential hidden relationships between various
biological processes in the specific condition under study, if such relationships exist.
This approach is described in detail in this chapter. In essence, the approach builds
a vector space model representation of the relationships between the genes and their
associated functions in the given condition, projects it in a lower-dimensional space in
order to eliminate the noise, and compares it with the corresponding null distributions
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of the same relationships in a reference built from known annotations in the absence
of any fold changes. Care has been taken to properly take into consideration the DAG
structure of the GO by eliminating any ancestor-descendant relationship, as well as
by using weights to properly capture information regarding the depth in the tree, the
number of annotations associated with a gene, the number of genes associated with
an annotation, etc.
4.1 Data representation
The set of all genes considered for an experiment, e.g. the list of all genes present
on a microarray used in the experiment, along with their annotations form a reference
data set R. Gene annotations are maintained in various public repositories such as
the ones provided by the GO consortium. Here, we used Onto-Express [Khatri et al.,
2002, Dra˘ghici et al., 2003] in order to obtain annotations for the genes in our data set.
We represent these genes and their functional annotations in a reference gene-function
matrix GFR with M rows and N columns, in a fashion similar to the term-document
matrix discussed in section 3.1. The rows and columns of this matrix represent the
genes and biological processes, respectively. The element aij of this matrix is 1 if and
only if gene i is involved in the biological process j, i.e.
GFRM×N = {aij} =


1 if gene i is annotated with
GO term j
0 otherwise
(4.1)
For obvious reasons, we discarded the ’unknown’ biological process from all data.
In GO, this is represented by the term, ’biological process’ (GO:0008150) and is the
root node in the domain of biological processes. It is commented on GO website
(http://www.geneontology.org/) as:
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“..this term is recommended for use for the annotation of gene products whose
biological process is unknown. Note that when this term is used for annotation, it
indicates that no information was available about the biological process of the gene
product annotated as of the date the annotation was made...”
The construction of gene-function matrix (GFR) is similar to the one described
in a previous work by our lab team (Khatri and Done) [Khatri et al., 2005a, Done
et al., 2009] with the exception that here we do not propagate gene annotations up in
the GO graph. It is to be noted that GO graph is defined in such a way that a gene
annotated to a specific term in the graph is assumed to be implicitly annotated with
all the parent terms, as well. The other difference is that we construct our matrix
using only the annotations associated with the genes on a microarray and not the
entire human genome, as was the case in our lab team’s previous work. In the next
section, we will see some more differences between the two studies. This matrix can
also be written as:
GFRM×N = (f1 f2 · · · fj · · · fN) (4.2)
where fj = (a1j a2j · · ·aMj)T is a function vector that describes the biological
process j. This matrix can also be described as:
GFRM×N =
f1 f2 . . . fN
g1
g2
...
gM


a11 a12 . . . a1N
a21 a22 . . . a2N
...
...
. . .
...
aM1 aM2 . . . aMN


(4.3)
In a given experiment, a subset of genes from R are found to be differentially
expressed (DE). The list of DE genes and their annotations form an experiment dataset
E ⊂ R. We use the genes and biological processes in E, to form a gene-function matrix
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GFE that will describe the given experiment:
GFEm×n = {aij} =


1 if DE gene i is annotated with
GO term j
0 otherwise
(4.4)
In this formula, m is the number of DE genes that are known to be involved in n
biological processes. Since the set of DE genes is a subset selected from the reference
set R, m ≤M and n ≤ N . This GFE matrix can also be described as:
GFEm×n =
f1 f2 . . . fn
g1
g2
...
gm


a11 a12 . . . a1n
a21 a22 . . . a2n
...
...
. . .
...
am1 am2 . . . amn


(4.5)
Since E ⊂ R, we can rearrange the rows and columns in GFR in such a way that
GFEm×n = GF
R
m×n, and is shown here:
GFRM×N =
f1 f2 . . . fn . . . fN
g1
g2
...
gm
...
gM


a11 a12 . . . a1n . . . a1N
a21 a22 . . . a2n . . . a2N
...
...
. . .
...
. . .
...
am1 am2 . . . amn . . . amN
...
...
. . .
...
. . .
...
aM1 aM2 . . . aMn . . . aMN


(4.6)
Each of the two gene-function matrices above will then be decomposed using a
singular value decomposition (SVD), which is described in the following section.
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4.2 Approximating matrix in lower dimensional subspace
The vector space model assumes that the gene and function vectors are linearly
independent. However, such an assumption is not valid, because the terms are defined
hierarchically in the GO graph. In addition, we ran analysis on the GO annotations
for the microarrays used in our data sets. Our analysis revealed that a certain (small)
number of terms in any random sample are annotated by most of the genes compared
to rest of the terms in the random sample. This creates a noise and problem in the data
similar to the one (like, polysemy and synonymy) discussed in chapter 3. Therefore,
we project our data, represented by vectors, in the gene-function matrix to a subspace
of lower dimensions and then reconstruct the approximated gene-function matrix. To
achieve this we apply SVD to both of our gene-function matrices.
The SVD of a p × q gene-function matrix GF , where p ≥ q, is a factorization of
the form [Golub and van Loan, 1983, Deerwester et al., 1990, Berry et al., 1995]:
GFp×q = Gp×l × Sl×l × F Tl×q (4.7)
where G and F are the matrices of left and right singular vectors, and S is the
l× l diagonal matrix of singular values, where l is the rank of GF (i.e. the number of
linearly independent rows or columns). The matrix S also decouples the expression of
each gene (function) vector from all other gene (function) vectors.
The diagonal values of matrix S have the property that s1 ≥ s2 . . . ≥ sl. In essence,
each singular value captures the amount of variability in the data along the direction
of the corresponding singular vector. Several of these singular values in the S matrix
are small and can be ignored without a significant loss of the features characterizing
the data. In this work we kept the first k largest singular values of the matrix S
corresponding to 80% of the variance in the data. In other words, k is the smallest
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index for which: ∑k
i=1 |si|∑l
i=1 |si|
≥ 0.80 (4.8)
The other singular values from k+1 to l, together with the corresponding columns
and rows in the matrices G and F T were eliminated. For the illustration of SVD see
chapter 3. This allows a projection of the data in a lower-dimensional space without
significant information loss. This reduced-dimensionality matrix will be:
GF k = Gk × Sk × F Tk (4.9)
Note that this approximation captures the most important features of the data
without losing any gene or function since the reduced gene-function matrix GF k has
the same dimensions as that of the original gene function matrix. Here, the subscript
k is used to denote the fact that these matrices are those corresponding to the first
k singular values rather than to indicate the dimensionality of the matrix as used in
Eq. 4.7 and before. This procedure is applied to both the original reference GFR, and
experiment GFE matrices.
The methodology described so far appears to resemble with the previous work by
our lab team (Khatri and Done) [Khatri et al., 2005a]; however, such similarity is only
superficial. In the previous work, our lab team constructed a matrix consisting of all
the annotations of the human genome from GO. In contrast, we construct two matrices
- one consisting of only the annotations related to a microarray under experiment,
and other related to the differentially expressed genes on that microarray. As such
our matrices do not need to contain the entire corpus of GO annotations related to a
given organism. Rather, our matrices represent a corpus and its subset local to the
genes on the microarray. Our technique exploits the local patterns in depth, which
otherwise may remain hidden in the whole corpus of GO annotations and noise.
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4.3 Association between biological processes
For each of the two GFk matrices constructed and approximated in the previous
sections, we can first center the data in their columns, and then calculate a covariance
matrix between all biological processes:
FFk = {σij} = GF Tk ×GFk (4.10)
as well as the corresponding correlation matrix:
R = {rij} =

 f
T
i × fj√
σ2i · σ2j

 =
{
σij√
σii · σjj
}
(4.11)
where fi and fj are two arbitrary function vectors whose data has been centered,
σij their covariance, and σ
2
i = σii and σ
2
j = σjj their variances, respectively. The
covariance matrix can also be written as:
FFk N×N =


σ11 σ12 . . . σ1n . . . σ1N
σ21 σ22 . . . σ2n . . . σ2N
...
...
. . .
...
. . .
...
σn1 σn2 . . . σnn . . . σnn
...
...
. . .
...
. . .
...
σN1 σN2 . . . σNn . . . σNN


(4.12)
The value of covariance σij for the reference gene-function matrix is different from the
value of covariance σij for the experiment gene-function matrix. This fact is illustrated
by the red colored elements in the matrix.
In essence, this generic correlation matrix captures the correlations between bio-
logical processes in a given state described by an arbitrary gene function expression
matrix. We will use this approach to calculate two specific correlation matrices. The
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first such matrix, denoted RE , is calculated from GFEk and captures the correlations
between all biological processes in the given condition. The second such matrix, de-
noted RR, is calculated from GFRk and represents the reference correlations intrinsic
to GO’s DAG structure.
Since the genes and functions represented by the GFE matrix are subsets of the
genes and functions represented by the GFR matrix, we reconstruct the RR matrix
to retain only those biological processes (columns) that are present in RE , and call
it R̂R. The element rRij ∈ R̂R represents the correlation between biological processes
i and j in the reference condition, based solely upon the known annotations. In
contrast, the element rEij ∈ RE represents the correlation between the same biological
processes in the given phenotype, based on the measured fold changes of all genes
known to be involved in biological processes i and j. The correlation thus computed
is an alternative form of finding the cosine similarity between biological processes
using centered data (explained in section 3.2). The advantage of using the concept
of correlation coefficients is that we can conveniently apply a parametric test to our
hypothesis presented in the next section.
4.4 Identifying significant changes
We are interested to identify those pairs of biological processes whose correlation
has significantly changed between the reference and the given experiment. Most hy-
pothesis tests assume that the data come from a distribution that is normal. However,
we know from chapter 3 that the correlation coefficient, r, varies between -1 and 1.
Fisher’s z−transform [Fisher, 1915] can be used to map the correlations into variables
that follow a normal distribution:
z =
1
2
ln
(
1 + r
1− r
)
(4.13)
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The standard error of this distribution is
√
1
η−3
, where η is the number of data
points used to compute r. In particular, for reference data R the value of η is M , and
for the experiment data E, the value of η is m.
We compute ZR and ZE values from R̂R and RE , respectively, using Eq. 4.13.
Here, we consider that the zR ∈ ZR value obtained in the absence of any fold changes
is the mean of the normal distribution followed by this particular correlation when
random (fold) changes occur. Our null hypothesis is that the zE ∈ ZE observed in the
given condition for a particular pair of biological processes is due to noise alone. The
research hypothesis is that the interaction between these two processes is significantly
changed in the given condition. The Z statistic to test this can be calculated as
follows [Zar, 2009]:
Z =
zE − zR√
1
m−3
(4.14)
Here, m is the number of data points (genes) used in the computation of rE .
Using this Z statistic, we can identify the pairs of biological processes whose cor-
relation has significantly altered in the given phenotype.
4.4.1 Correction for multiple tests
In statistical hypothesis testing, p-value represents the probability of rejecting a
null hypothesis when it is in fact true. For each test, we set a threshold of accepting
such mistakes and call it a Type I error (α). For example, when we choose an α level
of 0.05 for testing a hypothesis, there is a likelihood that we will make one mistake
every 20 times we apply the test. Every time we make a mistake, we predict a false
positive. In an experiment involving multiple tests in parallel, the likelihood of making
mistakes increases according to the number of tests performed. In the example above,
if we apply 20 tests in parallel, five of them are going to produce false positives.
Various methods have been proposed to address the issue of multiple tests. These
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methods usually set the alpha at the experiment level (αe), and adjust the α at
individual (test) levels. A direct way to adjust the value is given by:
α = 1− n√1− αe (4.15)
where n is the number of parallel tests in the experiment. This is also known as
Sidak correction. A closely related method was proposed by Bonferroni, which
approximates equation 4.15 and is described by:
α =
αe
n
(4.16)
An alternative way of applying this correction can be construed as follows. Compute
the p-value of a hypothesis test, multiply with n (to get what is known as a corrected p-
value), and test it against αe. If corrected p-value< αe, then reject the null hypothesis.
For a given experiment level αe, the value of α at individual level, in the above two
correction methods, depends upon the number of simultaneous experiments. For large
n, α becomes very small. In order to deal with the issue of large simultaneous tests,
alternative corrections have been proposed. For example, in a step-down Bonferroni
(also known as Holm’s step-wise) correction method, each individual level alpha is
adjusted differently according to the rank of computed p-values. All individual level
p-values are ranked from the smallest to the largest. The corrected p-values for each
rank is computed as:
1. corrected p-value = p-value× n
2. corrected p-value = p-value× (n− 1)
3. corrected p-value = p-value× (n− 2)
...
n. corrected p-value = p-value× 1
(4.17)
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We reject the null hypothesis whenever the corrected p-value of a test evaluates to
less than αe. A similar procedure for correction is known as the Benjamini and
Hochberg False Discovery Rate (FDR). For this correction, the individual level
p-values are ranked in ascending order, similar to the Holm’s step-wise correction, and
the corrected p-values are computed as:
1. corrected p-value = p-value× n
1
2. corrected p-value = p-value× n
2
3. corrected p-value = p-value× n
3
...
n. corrected p-value = p-value× n
n
(4.18)
The purpose of multiple tests correction methods is to reduce the false positives by
adjusting the p-value for each test. We used an αe = 0.05 and the False Discover Rate
(FDR) correction method. Alternatively, any other correction method can be used
depending upon the stringency required. FDR is considered less stringent compared
to the Holm’ step-wise correction method, which in turn is considered less stringent
than the other two correction methods (Bonferroni and Sidak).
We also discarded pairs of biological processes with absolute correlation coefficient
values of less than .20 since they indicate weaker correlation. Any pair involving a
biological process that was annotated with less than two genes was also discarded
from the final results. Depending upon the stringency requirements, any of these
parameters can be adjusted from one experiment to the other.
4.4.2 Bootstrapping
In order to find the significantly changed correlations, while taking into consider-
ation the potentially complex dependencies between various biological processes, we
used a bootstrap procedure. The bootstrap was performed by replacing the experi-
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ment data with a randomly selected set of m genes from the set of M reference genes
and their corresponding annotations, and by repeating the above described procedure
to compute, the corresponding matrices, correlations, and Z values. We repeated this
procedure 1,000 times and tracked the number of times a predicted functional asso-
ciation appeared with the same or more extreme Z value. The significance threshold
used was 0.05. Any biological processes pair that came up with a p-value less than
the threshold was selected as significant.
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Chapter 5: Improvements and enhancements
In the previous chapter, we presented a method that identified significantly changed
associations between biological processes using the binary representation of data in
gene function matrices. Here we will describe some of the weighting schemes that can
be applied to such GF matrices.
Matrices GFR and GFE in equations 4.1 and 4.4, respectively represent gene-
function data in binary format. Research in the area of information retrieval (IR)
shows that the weighted representation of information improves the quality of retrieval
over a binary representation based upon the assumptions that the repeated terms in a
document are well suited to describe the topic of the document, while infrequent terms
across the document collection are suited to differentiate between documents. We
think similar assumptions hold for the genes and their annotations. These assumptions
are discussed in section 5.3.
Since we have two gene-function matrices, we will use a two-letter notation sepa-
rated by a hyphen to denote the weighting scheme used in each case. The first letter
denotes the weight used for the GFR matrix, and the second letter denotes the weight
used for the GFE matrix. When a scheme enhances an existing scheme by assigning
additional weight to the elements of GF matrices, we prepend the enhancing scheme
acronym to the enhanced scheme name.
5.1 Binary scheme (1-1)
In the simplest version of our approach described above, we assigned 1-s to the
DE genes regardless of their actual expression change. This was done for both the
reference, as well as the experiment matrix (equations 4.1 and 4.1). Hence, we will
refer to this as 1-1.
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5.2 Weighting by gene expression levels (1-e)
The actual gene expression change can carry meaningful information. If genes
involved in different biological processes change in a coherently coordinated way, this
may indicate a couple or interaction between those biological processes. This fold-
change can be captured and taken into consideration during the analysis by redefining
our GFE matrix as described below.
GFEm×n = {aij} =


ei if DE gene i is annotated with
GO term j
0 otherwise
(5.1)
Here, ei is the normalized and log-transformed fold-change measured for gene gi
in the given condition. Normalization is performed by dividing each fold-change by
the absolute maximum of all fold-changes. Since in the reference condition, there are
no fold changes, we still use 1-s in the construction of the reference matrix GFR, as
described above (Eq. 4.1). Hence, this weighting scheme will be referred to as 1-e.
5.3 Information retrieval binary scheme (IR1-1)
We define our third scheme by adapting a weighting scheme commonly used in
information retrieval (IR). In this case, we will assign a weight wij to each element
of the gene-function matrix. This weight is computed as the product of two terms:
gene-bias (gbj) and inverse-annotation-bias (iabi). These terms are defined as follows:
wij = gbj · iabi (5.2)
gbj =
1
# of genes annotated with fj
(5.3)
iabi = −ln# of annotations for gi
Total annotations
(5.4)
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The term gbj is meant to remove the gene annotation bias in the GO. The GO
DAG is defined in such a way that general, broader terms are associated with the nodes
at the top of the DAG, while more specific terms are associated with nodes found in
the lower part of the DAG. Clearly, very specific terms provide more information and
tend to be associated with very few genes, while general terms are associated with a
lot of genes but they carry less information about each such gene. The term gbj tries
to quantitatively remove this bias by a factor inversely proportional to the number of
genes annotated with a given term.
Similarly, a gene annotated with fewer GO terms is either a good indicator of the
distinctive biological functions it participates in, or has not been studied much so far.
As annotation databases become more comprehensive, the former explanation will be
more likely. The term iabi exploits the former assumption and assigns higher weight
to a gene with fewer annotations.
With this IR-inspired weighting scheme our two matrices can be defined as follows:
GFRM×N = {aij} =


wij if gene i is annotated with
GO term j
0 otherwise
(5.5)
and
GFEm×n = {aij} =


wij if DE gene i is annotated with
GO term j
0 otherwise
(5.6)
where, wij is computed as described in equations (5.2 - 5.4). We will refer to this
weighting scheme as IR 1-1.
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5.4 Information retrieval scheme weighted by gene expression
levels (IR1-e)
In our fourth scheme, we use fold-changes of the DE genes for the GFE matrix in
the IR scheme and call it IR 1-e. The elements of GFE matrix for this scheme are
defined as follows:
GFEm×n = {aij} =


ei . wij if DE gene i is annotated with
GO term j
0 otherwise
(5.7)
The definition of GFR remains the same as defined in equation (5.5).
In this chapter we proposed some enhancements to our data model by adapting
the weighting schemes proposed for improved documents retrieval in the IR systems.
We applied our research model described in chapter 4 and using the above weighting
schemes to breast cancer and lung cancer datasets. In chapter 8, we discuss in detail
the selected results thus obtained. However, first we will look at the implementation
details of these methods in the next chapter.
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Chapter 6: Implementation details
Chapter 4 provides a statistical model to detect changes in the interaction between
biological processes in a given phenotype. In this chapter, we will focus on the imple-
mentation details of this model. This implementation can be divided into three main
modules:
• Data collection and gene-function matrix formation
• Model implementation
• Improvements integration
6.1 Data collection and gene-function matrix formation
High throughput experiments like microarrays produce gene expression data in
different conditions as explained in chapter 2. Researchers usually publish the results
or summary of these experiment, and occasionally upload the microarray data, used
in the experiment, on the world wide web for public access. Many publicly avail-
able databases such as Gene Expression Omnibus (GEO) at the National Center for
Biotechnology Information (NCBI), ArrayExpress at the European Bioinformatics In-
stitute (EBI), and Stanford Microarray Database (SMD) also archive and distribute
these microarray data.
Researchers, sometimes, select the genes of interest based on a statistical criteria
and provide that list along with the reference of microarray they used for the exper-
iment. We made the researchers selected genes as part of our experiment data set
(E). OntoTools [Khatri et al., 2007] back-end database maintains lists of genes on the
microarrays from various manufacturers like Affymetrix, Agilent, Clontech, Illumina,
etc. We used OntoTools back-end database to extract all the genes on the reference
microarray. These genes become part of our reference data set (R). When only a list
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of genes along with their fold-changes is provided, one can use the t-test with the
multiple comparisons correction to select the DE genes.
Depending on the microarray used in the experiment, the genes on that microarray
can be identified as probe identifiers (IDs), GenBank accession IDs, Unigenes cluster
IDs, gene symbols, Entez gene IDs, etc. National center for the biotechnology infor-
mation uses Entrez gene as a central resource for organizing information related to
genes [Maglott et al., 2005]. For the consistency of results and for the convenience
of researchers, we translated the genes in our data set to the Entrez gene IDs using
OntoTranslate [Dra˘ghici et al., 2006].
Gene Ontology (GO) provides a list of annotated genes for each of the associated
GO term. OntoExpress [Dra˘ghici et al., 2003] provides a web interface to extract
the functional profiles from GO related to a given set of genes. The set of genes
and annotations are maintained in an enterprise Oracle database and updated on
regular basis by the Intelligent Systems and Bioinformatics Laboratory (ISBL) [Khatri
et al., 2005b, 2006, 2007]. OntoExpress software can be used to extract the GO terms
annotated with the reference and DE genes of interest. I wrote a Java package, named
OntoInteractions, that calls the standalone routines of the OntoTools software to
translate the genes in our data set and extract the GO annotations from the OntoTools
back-end database. This allowed us to automate the process of annotation extraction
and to integrate the process into the rest of the implementation. OntoInteractions
package restructures the data in a format that represent our reference gene function
matrix (GFRM×N). The time for running this process depends upon the number of
genes in the reference data set. In the case of our reference gene function matrix for
breast cancer data set involving more than 24000 genes and 3600 biological processes,
it took approximately 30 minutes.
The reference gene function matrix also contains the rows representing the differen-
tially expressed (DE) genes and columns representing the biological processes related
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to the DE genes. We move these DE genes and corresponding biological processes to
the upper left part of the GFRM×Nmatrix. We use the first m rows corresponding to the
DE genes and the first n columns annotated to the DE genes to form the experiment
gene function matrix GFEm×n. The values of these two matrices are defined accord-
ing to equations 4.1 and 4.4. The software interaction between OntoInteractions and
OntoTools is illustrated in Figure 6.1.
6.2 Model implementation
Java (OntoInteractions package) provides a convenient way to generate reference
and experiment gene-function matrices. Software languages like R, MATLAB, and
Octave provide linear algebra and statistical packages that perform matrix computa-
tions in time efficient manner. I wrote another Java package named OntoJoctave
that provides an interface to the Octave language. This interface package provides
convenient classes and methods for communicating the commands and data between
the Java and Octave processes. Since Java stores a matrix (as 2D array) in a row-major
fashion and Octave stores a matrix in a column-major way, a transformation is nec-
essary for the correct communication of data between Java and Octave. OntoJoctave
package takes care of all such cases. All matrix operations involving singular value de-
composition and matrix approximation, correlation computation, Fisher z-transform,
and probability computation in statistical hypothesis testing were written as Octave
routines and called through the OntoJoctave interface. The main algorithm that ties
all these routines was written in the OntoInteractions Java package. Main logic of the
algorithm also incorporates bootstrapping procedure. The interface between Java and
Octave is illustrated in Figure 6.2.
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Figure 6.1: OntoInteractions gene-function processing interface. OntoInteractions
software module takes reference and experiment (DE) genes list as inputs, and ex-
tracts functional profiles from the OntoTools database. The module then processes
and arranges the genes and their functions (GO biological processes) into reference
and experiment GF matrices.
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OntoInteractions
Figure 6.2: OntoInteractions and OntoJoctave interface packages. OntoInteractions
take the reference and experiment GF matrices generated in the previous step (Fig-
ure 6.1, and applies the model discussed in chapter 4 using linear algebra and statis-
tical packages provided by Octave. The communication between Java and Octave is
handled by the Java-Octave interface (called OntoJoctave package). Finally, OntoIn-
teractions processes the results produced by Octave, and prints them out in a tabular
format.
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6.3 Improvements integration
It is clear from the discussion in chapters 4 and 5 that we keep our main statistical
model the same for all four schemes proposed for improving our prediction. The four
different weighting schemes relate to the construction of gene-function matrices. This
can be easily achieved by modifying our methods and calling the routines with appro-
priate parameters. Most of these parameters were stored in a separate configuration
file that was used as an input to our main driver program - OntoInteractions.
6.4 Hardware and software issues
Computing singular value decomposition (SVD) is computationally an expensive
operation. Although we approximate the original matrix with a reduced rank matrix
and only a partial SVD could be computed to achieve the desired matrix, we wanted
to compare various rank reduced gene-function matrices for choosing an optimal re-
duced rank. Some of the software packages we tried on our hardware were unable
to compute the full SVD. For example, a full SVD of a gene-function matrix of size
13000x3700 for our breast cancer data, on a 3.0 GHz Pentium 4 processor with 2
gigabytes of RAM, took almost 18-20 hours using the Java matrix (JAMA) package
(http://math.nist.gov/javanumerics/jama/). MATLAB, a commercial software
for performing mathematical operations, was unable to compute the full SVD with the
available memory for the same gene-function matrix. Another freely available pack-
age that comes with the language R (http://www.r-project.org/) was also unable
to compute the full SVD due to memory limitations. Freely available linear algebra
packages that come with GNU Octave (http://www.gnu.org/software/octave/)
was able to computes the full SVD of our gene-function matrix more efficiently. On
our new hardware with 2.4 GHz Intel core 2 duo with 4 gigabytes of RAM, Octave
was able to compute the full SVD of the same gene-function matrix in less than an
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hour. Computing the SVD using MATLAB on the same machine took at least 2 times
longer. Time for the SVD computation can be further reduced by computing only an
economical SVD. In economical SVD, the eigen vectors related to the null-space are
not computed. A null-space of a transformation matrix is the set of vectors that maps
the vectors from the domain space to null (zero) vectors in the range.
Computing SVD on the gene-function matrix formed by the differentially expressed
genes was not that expensive because of its smaller size compared to the reference
gene-function matrix size. However, iterating the procedure for 1,000 times during
bootstrapping adds up and dominates the total time to run the whole algorithm. For
example, in the case of breast cancer data, bootstrapping took approximately seven
hours.
Bootstrapping is a procedure that contains repetitive routines that can run in
parallel. ScalaPak (http://www.netlib.org/scalapack/)- a scalable linear algebra
package, provides routines to compute the SVD using parallel algorithm. However,
writing parallel programs adds complexity to the overall algorithm. If parallel algo-
rithm is implemented, it can reduce the overall software running time, significantly.
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Chapter 7: Literature review
7.1 Related work
Many studies have been conducted and methods developed to understand the
expression measurements on a genomic level. The most common approach in this
regard is the identification of the biological processes that are significantly over- or
under-represented in the set of DE genes [Khatri et al., 2002, Dra˘ghici et al., 2003,
Rhee et al., 2008]. The first step in methods following this approach involves the
selection of the differentially expressed genes, as stated in chapter 2, between a given
condition versus normal. This is done by means of a statistical test like t-test with a
chosen significance level (usually, p ≤ .05) and an arbitrary fold change (≥ 1.5) [Huang
et al., 2009, Dra˘ghici, 2003]. Next, the number of differentially expressed genes found
in each GO category of interest are compared with the number of genes expected to
be found in the same category just by chance. If the observed number is substantially
different from the one expected just by chance, the category is reported as significant.
The tests employed for this purpose usually include hypergeometric, binomial, Fisher
exact, and chi-square. We briefly describe these tests here.
Consider an experiment involving N genes. Suppose the researchers selected M
out these N genes to be differentially expressed in the experiment. Further suppose
that a functional category F in some ontology is annotated with nF out of N genes.
If mF out of M differentially expressed genes are associated with category F , then we
are interested in finding the significance of category F in the experiment. Some of the
methods that compute this significance are described below.
Hypergeometric distribution test
Let X be a variable that represents the number of randomly selected genes that
are associated with function F . The probability that exactly mF differentially genes
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are associated with category F , given that we randomly pick M genes out of N , is
given by the hypergeometric distribution:
P (X = mF |N, nF ,M) =
(
nF
mF
)(
N−nF
M−mF
)
(
N
M
) (7.1)
Here,
(
a
b
)
means a choose b (the number of possible ways b items can be chosen from
a total of n items) for any a and b, and is computed as:
(
n
m
)
=
n!
m!(n−m)! (7.2)
The probability that mF or fewer genes can be randomly associated with the cate-
gory F in the above experiment can be calculated as the sum of all probabilities for
X = 1, 2, ...mF , using equation 7.1. This represents the underrepresentation of cat-
egory F . If we want to compute over-representation of category F , we subtract the
underrepresentation P value from 1.0.
Binomial distribution test
One of the underlying assumptions for using hypergeometric test is that the random
sampling is performed without replacement. This restriction is important when the
number of items in a population is small. However, when the population is large,
we can replace this test with binomial distribution. In binomial distribution random
sampling is performed with replacement. If p = nF
N
is the proportion of the genes
associated with the category F , then the binomial probability of getting exactly mF
genes out of M genes randomly selected from a total of N genes is given by:
P (X = mF |M, p) =
(
M
mF
)
(p)mF (1− p)M−mF (7.3)
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Reference genes DE genes Total
Associated with category F nF mF RF
Not assoc. with category F nnonF = N − nF mnonF = M −mF RnonF
Total N M T
Table 7.1: A 2 x 2 contingency table. M out of N genes are found to be differentially
expressed in an experiment. nF out of N and mF out of M are found to be associated
with functional category F , respectively. RF , and RnonF are the row sums for the
number of genes associated with category F and not associated with category F,
respectively. N +M = T = RF +RnonF .
Chi-square test
When data for two variables is available for testing the equality of proportions, a
chi-square test can be performed using a contingency table [Pearson, Fisher, 1922]. A
contingency table, for example, in our situation is shown in Table 7.1. Here, RF , and
RnonF are the row sums for the number of genes associated with category F and not
associated with category F , respectively. Also, N +M = T = RF +RnonF .
The value of chi-square (χ2) statistic is computed as:
χ2 =
T
(|nF ·mnonF −mF · nnonF | − T2 )2
N ·M · RF · RnonF (7.4)
The above computed value is compared with the critical value of χ2 with one degree
of freedom (i.e. d.f = 1).
Fisher’s exact test
Chi-square test works well as long as any number in a contingency table (7.1) is
not less than 6. If this restriction cannot be observed, then an alternative test, called
Fisher exact test is applied:
χ2 =
N ! ·M ! · RF ! · RnonF !
T ! · nF ! · nnonF ! ·mF ! ·mnonF ! (7.5)
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These are the most common parametric tests applied to find the significance of a
functional category. Non-parametric tests similar to Kolmogorov-Smirnof using the
ranked set of genes is also used (e.g. in [Subramanian et al., 2005]). The computed
significant values suffer from the effects of multiple comparisons. Multiple compar-
isons, essentially, increases the chances of type-I error. Type-I error is the probability
of rejecting a null hypothesis, when it is correct. In order to compensate for this error,
the significance at the experiment level is fixed, and the p-value at individual level
is lowered by some (adjustable) factor. Various factor adjusting schemes have been
proposed. Bonferroni [Robinson et al., 2002, Shah and Fedoroff, 2004, Castillo-Davis
and Hartl, 2003], false discovery rate (FDR), Holm’s step-wise correction methods are
common among these.
Dra˘ghici and his team was among the first (in 2002) who developed a web based
graphical tool - OntoExpress [Khatri et al., 2002, Dra˘ghici et al., 2003], that allowed
users to perform chi-square, Fisher’s exact, and binomial tests for many organisms.
FunSpec [Robinson et al., 2002] was the other (in 2002) web-based tool that allowed the
hypergeometric test, but for the functional enrichment analysis of Yeast annotations
only. Soon after, many similar tools were developed. For example, GoMiner [Zee-
berg et al., 2003], FatiGO [Al-Shahrour et al., 2004], FACT [Kokocinski et al., 2005],
CLENCH [Shah and Fedoroff, 2004], GeneMerge [Castillo-Davis and Hartl, 2003],
DAVID [Dennis Jr. et al., 2003], GOstat [Beissbarth and Speed, 2004], FuncAssoci-
ate [Berriz et al., 2003] GOToolBox [Martin et al., 2004], etc. are some of the tools
that followed this approach. Hypergeometric test is the most popular among these for
the computation of gene enrichment scores.
As of 2005, there were at least 15 such tools focusing on this type of ontological
analysis [Khatri and Dra˘ghici, 2005]. Since then, even more tools have been developed.
Efforts have been made to improve this approach in various ways. For example, GSEA
[Subramanian et al., 2005] includes the entire list of DE genes rather than a subset
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of DE genes. Their approach tries to determine if the members of a given gene set
are randomly distributed through the ranked list of all genes, according to differential
expression between two classes. GSEA is based upon the expectation that gene sets
distribution related to the phenotypic distinction will tend to show on the top or
bottom of the ranked list. This approach uses Kolmogorov-Smirnof-like statistic to
compute enrichment score and its significance level. False discovery rate (FDR) is
employed to compensate for multiple comparisons. While GSEA uses a Kolmogorov-
Smirnof-like non-parametric technique, wherein an observed cumulative frequency is
compared with the expected frequency distribution [Zar, 2009], other related tools
(e.g. ErmineJ [Lee et al., 2005], MEGO [Tu et al., 2005], PAGE [Kim and Volsky,
2005], FatiScan [Al-Shahrour et al., 2007], Go-Mapper [Smid and Dorssers, 2004], etc.)
use parametric tests, such as z-score, t-test, permutation analysis, etc.
As stated in chapter 2, edges among nodes in the GO graph represent dependen-
cies, and a gene annotation to a particular node is shared by all of its ancestors.
Authors of some studies [Grossmann et al., March 2006, 2007, Alexa et al., 2006] re-
alized that the current tools performed functional enrichment analysis on individual
basis and ignored the fact that the terms in GO form hierarchical dependencies due
to the overlapping of annotations and the parent-child relations among the nodes.
Since nodes lower in the graph represent more specific terms in GO, Alexa and his
team proposed an elim method that removes genes annotated to a GO term, con-
sidered significant using Fisher’s exact test, from its ancestors. This process works
in a bottom-up approach, and has the disadvantage of not reporting the less specific
terms despite having high significance in the experiment. Authors of study realized
this and proposed an alternative weight method that down-weights genes connected
to less significant categories in the neighboring (parent and its child) subgraph. This
detects the locally most significant terms in the GO graph. Grossman and his team
proposed a method that computes the hypergeometric test for a functional category
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in the context of annotations to the parent of the term, and named it a parent-child
algorithm. In short, this method tries to avoid false positives related to the inheritance
problem.
These techniques considered the GO hierarchy and tried to resolve the related
issues. However, these techniques ignored the biological fact that most complex func-
tions in cells are carried out through the concerted activities of many gene products.
Current vocabularies such as provided by the GO are classified mostly based on in-
dividual gene functions as opposed to the functionality of a set of interacting genes.
Antonov and Mewes (2006) proposed a method to find over-representation of complex
functions annotated to a set of genes of interest, wherein a gene may belong simultane-
ously to two or more functional categories [Antonov and Mewes, 2006, Antonov et al.,
2008]. They defined the complex functional categories as algebraic combination of base
categories, such as by taking union, intersection or difference of the gene membership
set to the base categories. Membership is defined by the binary matrix of genes and
functions, and value of 1 or 0 indicates whether the gene in that row belongs to the
category in that column. Nam et al. (2006) also analyzed the differentially expressed
gene sets using composite GO annotations using a parametric (Z-) test [Nam et al.,
2006].
A very recent study by Huang et al. (2009) reviewed not less than 68 such
tools [Huang et al., 2009]. They classified various tools into three categories: singular
enrichment analysis; gene set enrichment analysis; and modular enrichment analysis.
We have discussed some tools, in this chapter above, from each of these categories in
the same order.
In our research methodology, we propose to find interactions among biological
functions through latent associations in the approximated matrix. A related set of
studies, but with different goals, has been reviewed here. For example, while sug-
gesting the prediction of gene functions based on patterns of annotation, King et al.
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(2003) proposed that if annotations for two attributes tend to occur together in a
database, then a gene holding one attribute is likely to hold the other as well [King
et al., 2003]. They modeled a decision tree and Bayesian network of GO relationships
in Saccharomyces Genome Database (SGD) and FlyBase data. They restricted their
technique to include only those terms that at least 10 genes were annotated as hold-
ing. Orgen et al. (2004) studied the compositional nature of GO terms and described
the dependencies among them [Ogren et al., 2004]. They observed that many GO
terms contain other GO terms as proper substrings and as such they convey impor-
tant semantic relationships. They suggested to exploit these substrings to suggest new
relations among GO terms to enhance annotation knowledge. Similarly, while working
on finding the consistency of GO terms, Burgun et al. (2004) observed relationships
among GO terms across three ontologies using ontological, lexical, and statistical ap-
proaches and suggested that these dependence relations can be used to produce more
consistent annotations [Burgun et al., 2004]. Kumar et al. (2004) also suggested re-
lationships among GO terms across three different ontologies using TIGR database
data set [Kumar et al., 2004]. They proposed the data mining rule association mecha-
nism to find such dependence relations. In our research, we are not interested in such
associations, as we are only interested in association among biological processes that
are not obviously evident from GO structure.
Bodenreider et al. (2005) investigated three non-lexical approaches to identify
associative relations in the GO and compared them among themselves and to the
lexical approaches [Bodenreider et al., 2005]. The three lexical approaches were: lex-
ical relations as studied in [Ogren et al., 2004], associative relations among concepts
in GO using MRREL, and co-occurrence of MeSH descriptors in MEDLINE records.
The three non-lexical approaches they studied were: computing similarity in a vector
space model, statistical analysis of co-occurrence of GO terms in annotation databases,
and association rule mining. The purpose of their study was to suggest new relations
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across three hierarchies of GO (and not among the terms in the same ontological
domain). However, their technique could identify only 12% of all the existing associa-
tions. Additionally, in our study, we are only concerned about the interactions among
annotations of biological processes.
7.2 Discussion of related work
The methods and techniques described in the previous section are in vogue almost
since the beginning of the decade and improved over the years. Numerous algorithms
incorporating these methods are listed on the Gene Ontology website. However, these
techniques ignore, in general, the fact that certain biological functions may interact
specifically with each other under certain stimuli or in a given phenotype. As such,
the above described techniques provide only a disjointed analysis in the context of
individual functional categories. Even when complex functional categories are consid-
ered, those techniques ignore the fact that the biological processes grouped together in
a complex category may interact with each other in the observed biological condition.
Consider the following hypothetical situation, for instance, that a DE gene ga is
annotated with a biological process A. Further suppose that under the same biological
condition another DE gene gb is annotated with a biological process B. The biological
process A might have been shown to interact in a specific condition, in another re-
search, with the biological process B. However, analysis tools may fail to provide such
information due to the nature and/or structure of the ontology and the database. As
such, the current methods and techniques, oblivious of any interaction between biolog-
ical processes, may only provide the two GO categories as over- or under-represented,
individually or together as a complex category.
We believe that such unusual interactions between biological processes, as pre-
dicted by our methods, has the potential to lead researchers in previously unexplored
directions or to help them, at least, better understand the phenomenon under study.
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We believe that our approach would help researchers broaden their insight into the
DE genes by providing more inclusive knowledge about the annotated biological func-
tions. Such an approach can be useful for all disciplines of life sciences ranging from
developmental biological to pharmaceutical research.
In the following chapter, we discuss in detail the selected set of biological processes
pairs obtained by applying our technique and methods to breast cancer and lung
cancer datasets.
68
Chapter 8: Results and discussion
We applied our methods on real data sets involving breast and lung cancer. These
data sets included genes identified as relevant for the prediction of breast cancer out-
come [Van’t Veer et al., 2002] and for the good and poor prognosis in patients with lung
adenocarcinoma [Beer et al., 2002]. After running each of the four weighting schemes
described above, we selected only those associations where the biological processes
involved were represented by at least two genes. Also, we ignored any relationships
that could be inferred exclusively from the GO structure without the use of any DE
genes (such as ancestor-descendant at any depths in the GO graph, etc.). We used a
significance threshold of 0.05, the false discovery rate (FDR) as the method for mul-
tiple comparison correction, and bootstrapping with 1000 iterations to establish the
significance in the presence of potential dependencies.
8.1 Results evaluation
Our analysis identified a number of pairs of biological processes that interact in
a statistically significant way in this condition. We categorized our predicted results
based on extensive literature review. We defined three categories:
1. Supported by the literature and considered trivial
2. Supported by the literature and considered non-trivial
3. Yet unknown or the association makes no sense
Table 8.1 summarizes the results for breast cancer, and Table 8.2 summarizes the
results for lung cancer.
All schemes produced results with an accuracy of almost more than 89%. Although
scheme IR 1-1 produced 100% accurate results for lung cancer data set, the same
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Number of predicted biological processes pairs
Scheme Cat. 1 Cat. 2 Cat. 3 Accuracy
Breast 1-1 10 5 1 93.7%
Breast 1-e 16 6 2 91.6%
Breast IR 1-1 9 7 2 88.8%
Breast IR 1-e 15 9 2 92.3%
Total 50 27 7 91.6%
Table 8.1: Results statistics for breast cancer data set. Cat. 1 represents the number
of predicted functional pairs supported by the literature and considered trivial; cat.
2 represents the number of predicted functional pairs supported by the literature and
considered non-trivial; cat. 3 represents the number of predicted functional pairs that
are yet unknown or make no sense.
Number of predicted biological processes pairs
Scheme Cat. 1 Cat. 2 Cat. 3 Accuracy
Lung 1-1 16 3 2 90.4%
Lung 1-e 39 3 2 95.4%
Lung IR 1-1 29 2 0 100.0%
Lung IR 1-e 38 9 3 94.0%
Total 122 17 7 95.21%
Table 8.2: Results statistics for lung cancer data set. Cat. 1 represents the number
of predicted functional pairs supported by the literature and considered trivial; cat.
2 represents the number of predicted functional pairs supported by the literature and
considered non-trivial; cat. 3 represents the number of predicted functional pairs that
are yet unknown or make no sense.
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scheme produced 89% accurate results for the breast cancer data set. The average
accuracy for all four schemes was more than 91% for breast cancer and 95% for lung
cancer data set. Subsets of results selected from each data set are shown in Table 8.3
and 8.4 and discussed in the following sections. The complete results can be found in
Appendix A and B.
8.2 Discussion and results for data in breast cancer
Veer observed [Van’t Veer et al., 2002] that “the breast cancer patients with the
same stage of disease could have markedly different treatment responses and overall
outcome.” The histopathological tests, such as lymph nodes status for cancer cells,
are used as predictors of metastases. However, such predictors may fail to accurately
classify breast tumors, for example, when the lymph nodes are tested to be negative in
primary breast cancer patients. In metastasis, malignant tumor cells break loose from
the primary tumor and form secondary tumors at other sites in the body [Alberts et al.,
2003]. Early Breast Cancer Trialists’ Collaborative Group conducted a worldwide
trial of 37,000 women and an analysis was presented in 1998 [Early Breast Cancer
Trialists’ Collaborative Group, 1998a,b]. According to their statistics, the risk of
distant metastases is reduced by chemotherapy or hormonal therapy by approximately
one-third. However, the same studies predicted that 70-80% of patients receiving this
treatment would have survived without it.
Veer signature genes predict prognosis of distant metastases in patients with pri-
mary beast cancer and lymph-node-negative (cancer free lymph nodes). They ex-
tracted RNA transcripts from tumors of 98 patients - 44 of them remained metastases
free at least for a period of five years. They hybridized these targets on a microarray
with approximately 25,000 genes and compared those with the hybridization of an-
other set comprising of the equally pooled RNAs from all 98 tumors. An initial set of
about 5,000 genes was selected with at least 2 folds change in expression values and
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with .01 p value.
They computed correlations between the prognostic category (metastasis vs. no-
metastasis) and the 5,000 significant genes. With the assumption that highly corre-
lated genes are possible candidates for reporting prognosis, they selected genes that as-
sociated with prognosis with correlation coefficient values of less than -0.3 and greater
than 0.3. They used these 231 genes in a supervised classification using the ’leave-
one-out’ method for cross-validation. They detected 70 signature genes that were
predictive of the good versus poor prognosis of metastases.
We used these 231 DE significant genes from an initial set of more than 24,000
(reference) genes. We translated these genes into Entrez gene identifiers (IDs) using
Onto-Translate [Khatri et al., 2006]. The mapping produced 19,292 reference and 147
differentially expressed Entrez Gene IDs. 13,201 of these initial genes were found by
Onto-Express [Khatri et al., 2002] to be annotated with 3,670 biological processes,
out of which 267 biological processes were annotated with 124 differentially expressed
genes. The matrix GFR thus constructed had a dimension of 13201× 3670, and GFE
had a dimension of 124× 267.
We applied our methods on this set of data, and identified a number of pairs of
biological processes whose correlation had significantly changed in the breast cancer.
Here, we will discuss a subset of such perturbed interactions.
Proteolysis and positive regulation of apoptosis
One of the statistically significant interactions was reported to happen between
proteolysis (GO:0006508) and positive regulation of apoptosis (GO:0043065). The
anaphase-promoting complex (APC) is known to regulate degradation of intracel-
lular proteins. It has been recently shown that UV (ultraviolet) radiation induced
human cell death by activating the proteolysis of CDH1, an APC activator, which
resulted in the accumulation of cell cycle proteins and thus facilitated UV-triggered
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Scheme GO Term 1 GO Term 2
FDR
p-value
Bootstrap
p-value
Common
Input
Genes
1-e,
IR 1-e
Proteolysis
Positive regulation
of apoptosis
0.00010 0.029 MMP9
1-1 Transcription
DNA replication
initiation
0.02601 0.043 MCM6
1-1
Regulation of
transcription,
DNA-dependent
DNA replication
initiation
0.00880 0.007 MCM6
1-1 DNA repair
Regulation of
transcription,
DNA-dependent
0.03368 0.020 BTG2
IR 1-1
Vesicle-mediated
transport
Transcription from
RNA polymerase
II promoter
0.00206 0.000 -
IR 1-1
DNA replication
initiation
Phosphoinositide-
mediated signaling
0.00001 0.000 -
Table 8.3: Selected pairs of biological processes that interact in a statistically signifi-
cant way in the breast cancer data set.
Figure 8.1: Association between Proteolysis and Positive regulation of apoptosis.
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apoptosis [Liu et al., 2008]. In addition, caspase-3, a member of cysteinyl aspartate
specific protease (caspase) family, was identified as a key mediator of mammalian cell
apoptotic cascade through proteolytic activation of various cellular proteins. One of
caspase-3 downstream targets is protein kinase C delta (PKCdelta), which is associ-
ated with dopaminergic cell death in parkinson’s disease [Kitazawa et al., 2003]. These
studies suggest that the two processes can be coupled in specific circumstances such
as reaction to UV radiation and parkinson’s disease. Our analysis shows that these
two processes are also linked in some way in breast cancer, which is consistent with
previous studies in [Chien et al., 2009, Lee et al., 2008b, Alkhalaf et al., 2008] show-
ing potential anti-tumor agents, such as quercetin, baicalein, and resveratrol, induced
tumor-cell specific apoptosis in a caspase 3-dependent manner. Interestingly, in our
analysis, the link between the two processes was not established by a substantial num-
ber of common genes (in this case there is only one common gene, MMP9, as shown
in Figure 8.1) but rather by the expression of the other 4 DE genes involved in prote-
olysis (PITRM1, RBP3, CTSL2 and PCSK6), which appeared to be correlated to the
expression of the other 3 DE genes involved in positive regulation of apoptosis. It is
also worth mentioning that no links can be established between these two processes
from the GO structure alone.
DNA replication initiation and transcription
DNA replication initiation and regulation of transcription-DNA depen-
dent
Our analysis also reported a statistically significant interaction between DNA repli-
cation initiation (GO:0006270) and transcription (GO:0006350), as well as between
DNA replication initiation (GO:0006270) and regulation of transcription-DNA depen-
dent (GO:0006355). In fact, the promoter region of mammalian aldolase B (AldoB)
gene has been discovered to have dual functions. In differentiated hepatoma cells,
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Figure 8.2: Association between DNA replication initiation and Transcription and
Regulation of transcription-DNA dependent.
it participates in the regulation of transcription as a normal promoter, while in de-
differentiated hepatoma cells, it is transcriptionally silenced and functions as an origin
of DNA replication [Miyagi et al., 2000, 2001, Zhao et al., 1994, Tsutsumi and Zhao,
1998]. Genome-wide studies showed that the DNA replication initiation sites and
transcription unit regions are coordinately mapped in the mouse genome, and the
location and type of the promoters were shown to be associated with the efficiency
and specificity of the replication origin (ORI) [Sequeira-Mendes et al., 2009]. Based
on this previous work, together with our findings reported here, we can suggest that
transcription may have a regulatory role in the initiation of DNA replication in breast
cancer, possibly through some promoter regions having a dual role, similar to that of
the AldoB promoter in hepatoma. Follow-up work in this direction could start with
the genes associated with these processes and also found to be DE in this condition:
MCM6, CCNE2, KIAA1442, EZH2, SEC14L2, BTG2, KIAA1442, and HMGB3; see
Figure 8.2. In fact, in the genome-wide studies mentioned above, it was revealed that
one of the DE genes included in our analysis, HMGB3, has a promoter that over-
laps with one of their newly identified CpG islands-associated ORIs [Sequeira-Mendes
et al., 2009].
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Figure 8.3: Association between DNA-dependent regulation of transcription and DNA
repair.
DNA-dependent regulation of transcription and DNA repair
Another statistically significant interaction was reported between DNA-dependent
regulation of transcription (GO:0006355) and DNA repair (GO:0006281). In higher
eukaryotes, one essential mechanism to maintain the accuracy of DNA-dependent
transcription is transcription-coupled repair (TCR), in which case DNA lesions lo-
cated on the actively transcribed strand of expressed genes is preferentially repaired
compared to the non-transcribed strand. This mechanism suggests a direct correla-
tion of transcriptional regulation and DNA repair mediated by RNA Polymerase II
basal transcription factor TFIIH, disruption of which causes multiple organ disorder
and is usually fatal [Sarker et al., 2005]. Our analysis suggests that the two processes
are also associated in breast cancer, possibly through shared key regulators. In fact,
the protein encoded by one of the predominant tumor suppressor genes, breast can-
cer 1 (BRCA1), has been found to directly participate in activation of transcriptional
regulation complex and DNA repair machinery in response to DNA damage, link-
ing the maintenance of chromosomal stability to tumor suppression, possibly through
transcription-coupled DNA repair [Venkitaraman, 2001]. It would be noteworthy to
investigate factors interacting with genes found to be DE in breast cancer and involved
in those processes, such as MCM6, KIAA1442, EZH2, HMGB3, BTG2, and CCNE2
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Figure 8.4: Association between Vesicle-mediated transport and Transcription from
RNA polymerase II promoter.
(Figure 8.3), for the purpose of identifying regulator(s) of both processes as potential
anti-cancer drug target(s).
Vesicle-mediated transport and transcription from RNA polymerase II
promoter
While several of the significant interactions detected by our analysis involved bio-
logical processes that have one or more annotated gene(s) in common, some interac-
tions were reported between processes that have no common genes whatsoever. Such
interactions are particularly important since no connection between those biological
processes can be established based on existing annotations alone. One example is that
of vesicle-mediated transport (GO:0016192) and transcription from RNA polymerase
II promoter (GO:0006366) and is shown in Figure 8.4. O’Connor and his colleagues
characterized the mechanism underlying the cell secretion stimulus-transcription cou-
pling of chromogranin A, and their studies suggested that these two biological processes
are closely related [Tang et al., 1996, 1997, 1998, Mahata et al., 2003]. Chromogranin
A is known to be one of chromaffin granule neurotransmitters involved in the diagno-
sis of pheochromocytoma [Hsiao et al., 1991]. In the presence of extracellular stimuli,
chromogranin A stored in small intracellular secretory vesicles is released from chro-
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Figure 8.5: Association between DNA replication initiation and Phosphoinositide (PI)-
mediated signaling.
maffin cells, and the transcription of its own gene gets re-activated paralleling the
secretion. These studies showed a tight correlation between vesicle-mediated secretion
and transcription of chromogranin A, which is highly dependent on precise regulation
of intracellular calcium level. Our findings suggest that a similar mechanism may
contribute to the progression of breast cancer, in which case increased growth factor
secretion from the mammary gland may result in an activation of its own or other
gene expression, possibly through the secretion-coupled transcription pathway. In-
deed, abnormal secretion of growth factors, including insulin-like growth factor I and
II (IGF-I, IGF-II), has been reported to be associated with multiple breast cancer cell
lines [Huff et al., 1986, Wang et al., 2008].
DNA replication initiation and phosphoinositide (PI)-mediated signaling
Another interesting interaction change was detected between DNA replication ini-
tiation (GO:0006270) and phosphoinositide (PI)-mediated signaling (GO:0048015).
PI-mediated signaling pathway plays a crucial role in a variety of cellular functions,
including cell growth, proliferation, differentiation, survival, etc. One major signal
transducer in this pathway is the proto-oncogene protein phosphoinositide 3-kinase
(PI3K), which interacts with multiple tumor progression and metastasis pathways,
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therefore serves as a good candidate drug target in cancer therapy [Fry, 2001]. In
addition to its regulatory role in DNA transcription and translation, PI3K also plays
an important part in the initiation of DNA synthesis through modulating stabilization
of c-Myc oncogenic transcription factor, a key regulator involved in precise control of
cell cycle progression [Bader et al., 2005, Kumar et al., 2006, Dominguez-Sola et al.,
2007]. Based on this previous work, together with our findings, our analysis suggests
that PI signaling may contribute to breast cancer through DNA replication-related
mechanisms, in which case deregulation of PI3K activity possibly induced by abnor-
mal level of growth factors may lead to enhanced amplification of DNA materials,
which facilitates cell proliferation in tumor progression. Follow-up work in this di-
rection would be identification of putative interactions between PI-mediated signaling
pathway and the two genes associated with DNA replication initiation and found to
be DE in breast cancer, MCM6 and CCNE2. It is also worthy to point out that in
the condition of breast cancer, the link between the two processes was identified as
significantly changed with totally distinct sets of DE genes.
A list of significant interactions between biological processes discussed here are
shown in Table 8.3. A complete list of results, related to lung cancer dataset, can be
found in appendix A.
8.3 Discussion and results for data in lung cancer
A ten year survey of 713,043 primary lung malignancies, their treatment and pa-
tients survival [Fry et al., 1999] (and related studies [Pairolero et al., 1984, Naruke
et al., 1988]) showed that around 35-50% of patients with lung cancer stage I dis-
ease developed it again within five years. Realizing the fact that Histopathology was
“insufficient to predict disease progression and clinical outcome in lung adenocarci-
noma”, Beer et al. (2002) employed statistical regression and clustering techniques on
microarray gene expression data to predict survival of patients with early stage lung
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Figure 8.6: Association between Anti-apoptosis and Inflammatory response.
adenocarcinoma.
They measured gene-expression profiles for 86 primary lung adenocarcinomas that
included 67 stage I tumors. ’Affymetrix human gene fl’ microarray was used to measure
expression levels. A custom algorithm was used to find the transcript abundance. The
data was trimmed of genes with extremely low expression levels, and genes most related
to survival were identified with univariate Cox analysis.
Our second dataset consisted of genes identified as significantly different between
good and poor prognosis in patients with lung adenocarcinoma [Beer et al., 2002]. The
mapping of the microarray Affymetrix human gene fl probes returned 5541 reference
and 96 differentially expressed Entrez gene IDs. 5037 of these initial genes were found
by Onto-Express to be annotated with 2908 biological processes, out of which 248
biological processes were annotated with 87 differentially expressed genes. The matrix
GFR thus constructed had a dimension of 5037× 2908, and GFE had a dimension of
87× 248.
A subset of results obtained for this data set is shown in Table 8.4 and discussed
below. The complete list of results can be found in Appendix B.
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Scheme GO Term 1 GO Term 2
FDR
p-value
Bootstrap
p-value
Common
Input
Genes
IR 1-1 anti-apoptosis
Inflammatory re-
sponse
.000000 .031 RELA
1-1,
IR 1-e
Interspecies inter-
action between or-
ganisms
Negative regula-
tion of apoptosis
.039476 .015 KRT18
1-e,
IR 1-e
Wnt receptor sig-
naling pathway,
calcium modulat-
ing pathway
Cell differentia-
tion
.000000 .026 WNT1
IR 1-e Blood coagulation
Negative regula-
tion of cell cycle
.046280 .020 -
IR 1-e
Negative regulation
of cell cycle
Cell adhesion .000000 .019 -
Table 8.4: Selected pairs of biological processes that interact in a statistically signifi-
cant way in the lung cancer data described in [Beer et al., 2002].
Anti-apoptosis and inflammatory response
While most of the interactions between biological processes in Van’t Veer’s dataset
involved generic processes occurring in almost all types of cells, such as DNA repli-
cation, transcription and apoptosis, interactions identified in Beer’s dataset involved
very specific biological processes that occur in only a subset group of cells, includ-
ing blood coagulation, inflammatory response, and cellular defense response. For
instance, our analysis reported a statistically significant interaction between anti-
apoptosis (GO:0006916) and inflammatory response (GO:0006954) - see Figure 8.6.
Inflammatory response is an important protective mechanism in response to infec-
tions and/or traumatic damages, removing the invading stimuli as well as initiating
the healing process. Inflammation is known to be associated with various kinds of
cancer, in which condition the balance between cell proliferation and cell death in nor-
mal stage is interrupted due to loss of cell cycle checkpoint control and/or suppression
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of the apoptosis machinery [Coussens and Werb, 2002, Balkwill et al., 2005]. Many
inflammatory factors contribute to tumor progression in liver, stomach and/or intes-
tine tissues, among which a key player is the nuclear factor kappa B (NF-kappaB).
It gets activated during inflammation response and subsequently triggers expression
of downstream anti-apoptotic genes, further enhancing tumor cell survival [Pikarsky
et al., 2004, van der Woude et al., 2004]. Our analysis suggests that inflammation may
play a similar role in promoting lung carcinogenesis, possibly through the release of
signals that induce inhibition of apoptosis in cancer cells. Indeed Sulindac and other
non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) that target inflammatory
cytokines attenuate lung cancer development with induced cell apoptosis [Berman
et al., 2002]. Follow-up work in this direction could start with the inflammation-
associated factors RELA, BMP2, and TNFAIP6 that were found to be DE in lung
cancer for their potential interactions with anti-apoptosis pathways. In fact, TNFAIP6
(tumor necrosis factor alpha induced protein 6), also known as TSG-6, has been iden-
tified as a potential target of hypoxia-inducible factor(HIF)-1alpha on its inhibition
of human small cell lung cancer (SCLC) cell apoptosis [Wan et al., 2009].
Interspecies interaction between organisms and negative regulation of
apoptosis
Another example of change in correlation detected by our analysis is between in-
terspecies interaction between organisms (GO:0044419) and negative regulation of
apoptosis (GO:0043066). As one major type of interspecies interactions, infection
happens when a foreign species (virus or bacterium) invades a host organism (say, hu-
man) and interferes with its normal functioning, which may lead to severe diseases and
cancer [Parsonnet, 1995]. Parasitic bacteria species, such as Toxoplasma gondii (cause
of toxoplasmosis), inhibit the apoptosis of infected host cells possibly by interfering
with the caspase cascade, therefore increasing their survival opportunity [Keller et al.,
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Figure 8.7: Association between Interspecies interaction between organisms and Neg-
ative regulation of apoptosis.
2006]. Moreover, hepatitis B (HBV) virus infection, the major cause of hepatocellular
carcinoma (HCC), activates over-expression of apoptosis inhibitors in the host cells
[Lu et al., 2005]. These studies indicate a clear interaction between the two processes
in the circumstances of toxoplasmosis and liver cancer.
Even more relevant literature links viral infection with lung cancer and adenocar-
cinoma in particular. Klein and Zheng reported an important role of oncogenic viruses
such as human papillomaviruses (HPVs) and JC virus in lung carcinogenesis [Klein
et al., 2009, Zheng et al., 2007]. Our data indicate that the two processes may be
coupled in some way in lung cancer, in which case virus-induced negative regulation
of apoptosis in the host cells may be the mechanism through which cells invaded by
the virus escape death and start immortalization. Consistent with this, significant
down-regulation of apoptosis inducers, including tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL), was observed in immortal LiFraumeni syndrome
(LFS) cells compared to normal condition [Kulaeva et al., 2003]. Of the four DE genes
(FADD, KRT7, KRT19, and KRT18; see Figure 8.7) annotated to be associated with
interspecies interaction, FADD (fas-associated protein with death domain) initiates
apoptosis through death-receptor signaling while the epithelial keratin protein KRT18
plays a role in cell resistance to drug-induced apoptosis [Chinnaiyan et al., 1995, Os-
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Figure 8.8: Association between Wnt receptor signaling pathway, calcium modulating
pathway and Cell differentiation.
hima, 2002]. Therefore, interesting follow-up work would be to investigate their poten-
tial interaction with proteins produced by the lung cancer-related viruses. In fact, one
major mechanism in which the adenoviruses (cause of respiratory infections) manage
to establish a long-term infection is to inhibit the host cell’s apoptosis by blocking the
interaction between FADD and death effector filaments, which is mediated by the viral
protein E1B [McNees and Gooding, 2002], suggesting those interspecies interaction-
related DE genes may serve as good candidate targets for anti-cancer therapy.
Wnt receptor signaling pathway, calcium modulating pathway and cell
differentiation
Our analysis also found a significant change of correlation between Wnt receptor
signaling pathway, calcium modulating pathway (GO:0007223), and cell differentia-
tion (GO:0030154). Different from the canonical Wnt signaling pathway which is de-
pendent on the transcription factor beta-catenin, Wnt/calcium pathway is triggered
by the Wnt5a class (Wnt5a, Wnt4, Wnt11). resulting in activation of two calcium-
sensitive kinases, calmodulin-dependent protein kinase II (CamKII) and protein kinase
C (PKC) [Du et al., 1995, Moon et al., 2004, Pongracz and Stockley, 2006]. In addition
to its established role in embryonic dorsal-ventral patterning, there is also evidence
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Figure 8.9: Blood coagulation and Negative regulation of cell cycle.
that Wnt/calcium signaling participates in metastasis through modulation of cell pro-
liferation and motility mediated by Wnt5a [Liang et al., 2003, Weeraratna et al., 2002].
More evidence exists linking Wnt/calcium pathway to lung cancer. For example, Lee
reported significant expression level changes of multiple non-canonical Wnt signaling
components including Wnt5a and Wnt11 in squamous cell lung cancer cells compared
to normal cells [Lee et al., 2008a]. Our data suggest a regulatory role of Wnt/calcium
pathway in lung cancer related to cell differentiation, possibly in a way that deregu-
lation of Wnt/calcium signals lead to de-differentiation of fully developed lung cells,
resulting in uncontrolled cell growth and eventually malignant stage. Consistent with
this, the data of Pandur support a role of Wnt11 in promoting cardiac differentiation
through activation of Wnt/calcium signaling mediator PKC [Pandur et al., 2002]. In
addition, together with Wnt5a, Wnt11 also regulates the differentiation pattern of
myogenic cells in limb development [Anakwe et al., 2003]. Follow-up work in this
direction could start with the two DE Wnt ligands in lung cancer (WNT10B, WNT1)
that were annotated to be associated with Wnt/calcium signaling. See Figure 8.8 for
the associated DE genes.
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Blood coagulation and negative regulation of cell cycle
While most significantly interacting biological processes detected in our study have
at least one gene in common, approximately thirty cases with distinct input genes
sets are of particular interest. One example of that involves the blood coagulation
(GO:0007596) and negative regulation of cell cycle (GO:0045786) - Figure 8.9. One
candidate mediator that possibly establishes the bridge between the two process is
the serine protease prothrombin. It plays a critical role in blood coagulation. Pro-
thrombin is converted into its active form, thrombin, and promotes the formation of
blood clots by converting soluble fibrinogen into insoluble fibrin [Yegneswaran et al.,
2003]. Abnormally prolonged prothrombin time, an indication of reduced coagulation
function, associated with aggravated stage in cases of gastric and lung cancer [Kwon
et al., 2008, Buccheri et al., 1997]. Moreover, data of [Carr et al., 2007] supported
that prothrombin is involved in cell cycle regulation as a DNA synthesis inhibitor,
possibly through an induction of cytoskeleton de-organization. This inhibition was
only observed in hepatocytes but not in hepatoma cells likely due to different extra-
cellular matrix (ECM) protein interactions in normal versus cancer condition. These
previous studies clearly indicated a regulatory role of blood coagulation factor(s) in
cell cycle progression. Our results suggest that a similar mechanism may exist in lung
cancer, in which case the two processes interact in a way that dysregulation of blood
coagulation mediators activated in clotting cascade causes interruptions in cell cycle
control, resulting in unlimited cell proliferation and growth. Follow-up work in this
direction could start with the genes identified to be DE in lung cancer and associated
with these two processes, SERPINE1, ITGA2, BMP2, and INHA. In fact, one of the
blood coagulation-associated DE gene SERPINE1 (serine protease inhibitor, clade E,
member 1), participates in cell proliferation promotion through inducing cell cycle
re-entry as part of the wound repair program in replicatively competent keratinocytes
[Qi et al., 2008].
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Figure 8.10: Association between negative regulation of cell cycle and cell adhesion.
Negative regulation of cell cycle and cell adhesion
Another interesting interaction change was detected between the negative regula-
tion of cell cycle (GO:0045786) and cell adhesion (GO:0007155). As part of the tumor
micro-environment (stroma), reduced cell adhesion is often observed between tumor
and normal cells [Behrens, 1993]. Abnormal expression of cell adhesive molecules,
such as integrins, catenins, and E-cadherins, has been reported to interact with vari-
ous intra- and/or extra-cellular signaling factors and promote tumor progression [Sung
et al., 2007]. One example of that is B-cell non-Hodgkin lymphoma (NHL), in which
case the lymphoma cells are maintained in a dormant stage when attached to bone
marrow stromal cells, but re-enter proliferation upon detachment and progress into
metastasis thereafter. This is due to a cell adhesion-induced reversible cell cycle ar-
rest in adherent lymphoma cells via up-regulation of cyclin-dependent kinase inhibitor
(CDKI) p27, and the arrest is removed when dissociation happens [Lwin et al., 2007].
Based on this previous work, together with our findings, we can suggest a regulatory
role of cell adhesion in cell cycle progression in lung cancer development. Consistent
with this, E-cadherin-catenin complex, the critical mediator of normal cell-cell contact,
is associated with lung carcinogenesis [Bremnes et al., 2002]. Moreover, other existing
studies support E-cadherin as a growth inhibitor in mammary carcinoma cells through
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inducing cell cycle arrest, which is associated with elevated protein level of p27, the
same factor that mediates the dormancy of lymphoma cells in NHL [St Croix et al.,
1998]. According to records in the human lung cancer database (HLungDB) [Wang
et al., 2010], accumulating evidence links p27 to lung cancer and lung adenocarcinoma
in particular [Landi et al., 2008, Spira et al., 2007, Wrage et al., 2009]. Interestingly, in
the Genes-to-Systems Breast Cancer (G2SBC) database [Mosca et al., 2008, Viti et al.,
2009], the expression profile of p27 is highly correlated to that of TPBG (trophoblast
glycoprotein), one of the cell adhesion-associated DE genes in our study. Therefore,
follow-up work in this direction could start with the five DE genes involved in cell-cell
contact, TPBG, RND3, ITGA2, LAMB1, and TNFAIP6, for their possible interactions
with cell cycle regulators in the cases of lung cancer.
In this chapter, we presented the results obtained from breast cancer and lung
cancer data sets by applying our model and schemes presented in chapters 4 and 5.
We also presented statistics evaluating our resuts.
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Chapter 9: Conclusions and future directions
In this work, we presented a method that analyzes gene expression data obtained
from a microarray experiment together with all existing gene annotations to find sta-
tistically significant interactions between specific biological processes involved in the
given biological condition. We represented all the genes on a microarray and their an-
notated biological processes as a matrix in the vector space model. We, then projected
the vectors in the lower dimensional space and reconstructed the approximated matrix
using rank reduction. After centering the data in approximated matrix, we computed
associations among biological processes using Pearson correlation coefficients. We also
performed the same procedure on the biological processes annotated with genes found
to be differentially expressed in the biological condition under observation. We then
compared the correlation between biological processes, computed by differentially ex-
pressed genes, with the corresponding null distributions of the same relationships in a
reference built computed from all the genes on the microarray. The significance values
were computed using z-test and adjusted for multiple comparison using FDR.
Inherent dependencies among the terms, due to the hierarchical structure of GO,
can skew the results of any method using the GO. To avoid such skewness, we elimi-
nated any ancestor-descendant relationships from our predicted biological pairs. We
also used the weights to capture the information regarding the depth in the tree, the
number of annotations associated with a gene, the number of genes associated with
an annotation, etc. We also applied the bootstrapping method with 1000 iterations to
remove any bias or additional dependencies in the data. We detailed out our method-
ology in chapter 4 and then presented improvements to our method in chapter 5.
Applying the proposed method to two independent data sets yielded a number of
interesting statistically significant interactions specific to the the given phenotypes.
Most of these interactions are well supported by independent studies from the litera-
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ture. A subset of such interactions was discussed in details in chapter 8 and shown to
have the potential to open a number of new avenues for research in lung and breast
cancer.
9.1 Limitations
We are aware of the fact that the correlation coefficient only captures the linear re-
lationship between two (data) variables. Real life biological mechanisms are complex
and non-linear. As such any linear model will not be able to capture all the com-
plexities of the underlying biology. The complex biological systems require complex
mathematical and statistical models to represent them. However, any complex model
poses not only the extra intellectual challenges but computational hurdles, as well.
Our results showed that correlation coefficients, in conjunction with latent semantic
indexing technique, can still be useful to linearly approximate the complex biological
system.
9.2 Future directions
Although we restricted ourselves to the biological processes of GO terms, our model
is not restricted to any particular ontology, and can be used with any type of anno-
tations. Our model can also be applied to any set of reference and a selected set of
genes and not just genes used in a microarray experiment.
In addition, a relationship between two biological processes, as predicted by our
method, can also:
• be used in methods predicting novel gene annotation when one of the functions
in the relationship is already known to be annotated with a gene and the other
is not;
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• reveal a quantitative strength of the (linear) relationship - a biological interde-
pendence or interaction - among GO terms that cannot be inferred easily from
existing literature and that may be specific to the given condition; and
• suggest novel gene networks or possible interconnections in a gene network
formed by the genes annotated with predicted associated terms.
As such, these functional relationships have the potential to broaden the knowledge-
base of research and enhance our understanding of biological phenomenon under study.
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Appendix A: Results for breast cancer data
We applied our method, presented in chapter 4, on breast cancer dataset (Van’t
Veer 2002) using the four weighting schemes presented in chapter 5. The results for
each of the four weighting schemes have been summarized in columns. These columns
have been described below.
FDR - FDR p-value:
An association between biological processes is computed using Pearson correlation
coefficient after reducing the gene functions matrices using SVD. These correlation
coefficient values are mapped to the z-values using Fisher exact transformation. These
z-values corresponding to the biological processes annotated with the differentially
expressed genes are compared against the null distribution in the reference built using
Z-test. Corresponding p-values are computed. These p-values are adjusted using False
Discovery Rate (FDR). The adjusted p-values are presented in this column.
Boot - Bootstrap p-value:
We ran bootstrap procedure on our method(s) with 1000 iterations and compute
the p-values. Significant pairs of biological processes are chosen based upon the boot-
strap p-values represented in this column.
Function A:
One of the functions (biological processes in the GO) in the predicted functional
pair.
Function B:
The other function (biological process in the GO) in the predicted functional pair.
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Inputs (A and B)
The input genes that are annotated with function A and function B. The two sets
are grouped separately in parenthesis with letters A or B to identify which functional
category they belong to.
Cat. - Category:
We defined three categories numbered 1 to 3. Each functional pair (association),
after extensive literature review, is assigned to one or more categories. These categories
were defined as, category 1: supported by literature and considered as trivial; category
2: supported by literature and considered non-trivial; and category 3: yet unknown
or the association makes no sense.
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Table A.1: Breast cancer results for scheme 1-1
FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.000000 .002 positive regulation of
ubiquitin-protein ligase
activity during mitotic
cell cycle
anaphase-promoting
complex-dependent
proteasomal ubiquitin-
dependent protein
catabolic process
A(PSMD7, PSMD2, FBXO5)
B(PSMD7, MAD2L1,
PSMD2)
1
.011450 .006 regulation of transcrip-
tion, DNA-dependent
negative regulation of
cell proliferation
A(MCM6, KIAA1442, EZH2,
HMGB3, BTG2) B(TGFB3,
BTG2)
1
.008800 .007 regulation of transcrip-
tion, DNA-dependent
DNA replication initia-
tion
A(MCM6, KIAA1442, EZH2,
HMGB3, BTG2) B(MCM6,
CCNE2)
2
.012550 .008 transcription negative regulation of
cell proliferation
A(MCM6, KIAA1442, EZH2,
SEC14L2, BTG2) B(TGFB3,
BTG2)
1
.000330 .009 signal transduction cell-cell signaling A(GPSM2, IGFBP5, LRP12,
GNAZ, STK3, MAPRE2,
EXT1, MS4A7, WISP1,
TGFB3, GPR126, NMB,
ADM, NMU, VEGF, FGF18)
B(DLG7, WISP1, TGFB3,
NMB, ADM, FGF18)
1
.035880 .014 positive regulation of
cell proliferation
protein amino acid de-
phosphorylation
A(FLT1, CDC25B, TBX3,
ADM, VEGF, FGF18)
B(CDC25B, MTMR2)
1
.035730 .016 cell differentiation transport A(FLT1, STMN1, HRB, RIP)
B(RBP3, SEC14L2, SLC7A1,
HRB, RIP)
1
.001460 .018 interspecies interaction
between organisms
anatomical structure
morphogenesis
A(KRT18, CENPA, SYN-
CRIP, IVNS1ABP) B(KRT18,
FGF18)
2
or
3
.000280 .018 nucleosome assembly interspecies interaction
between organisms
A(TSPYL5, CENPA)
B(KRT18, CENPA, SYN-
CRIP, IVNS1ABP)
2
.033680 .020 regulation of transcrip-
tion, DNA-dependent
DNA repair A(MCM6, KIAA1442, EZH2,
HMGB3, BTG2) B(BTG2,
RFC4)
2
.000000 .021 skeletal development anti-apoptosis A(MMP9, MATN3, TBX3)
B(BIRC5, TBX3)
1
.002380 .026 positive regulation of
cell proliferation
multicellular organis-
mal development
A(FLT1, CDC25B, TBX3,
ADM, VEGF, FGF18)
B(FLT1, KIAA1442, HMGB3,
STMN1, TBX3, VEGF, HRB,
RIP, RPS4X)
1
p-val p-val Continued on next page . . . Breast Cancer:1-1
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FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.000000 .028 negative regulation of
cell proliferation
DNA repair A(TGFB3, BTG2) B(BTG2,
RFC4)
2
.000200 .043 cell differentiation female pregnancy A(FLT1, STMN1, HRB, RIP)
B(FLT1, ADM)
1
.026010 .043 DNA replication initia-
tion
transcription A(MCM6, CCNE2) B(MCM6,
KIAA1442, EZH2, SEC14L2,
BTG2)
2
.006550 .049 anatomical structure
morphogenesis
negative regulation of
apoptosis
A(KRT18, FGF18) B(KRT18,
BTG2, VEGF, ASNS)
1
p-val p-val Breast Cancer:1-1
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Table A.2: Breast cancer results for scheme 1-e
FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.000000 .000 signal transduction cell-cell signaling A(GPSM2, IGFBP5, LRP12,
GNAZ, STK3, MAPRE2,
EXT1, MS4A7, WISP1,
TGFB3, GPR126, NMB,
ADM, NMU, VEGF, FGF18)
B(DLG7, WISP1, TGFB3,
NMB, ADM, FGF18)
1
.000000 .000 transcription transport A(MCM6, KIAA1442, EZH2,
SEC14L2, BTG2) B(RBP3,
SEC14L2, SLC7A1, HRB,
RIP)
3
.000000 .005 positive regulation of
ubiquitin-protein ligase
activity during mitotic
cell cycle
anaphase-promoting
complex-dependent
proteasomal ubiquitin-
dependent protein
catabolic process
A(PSMD7, PSMD2, FBXO5)
B(PSMD7, MAD2L1,
PSMD2)
1
.000010 .009 positive regulation of
cell proliferation
signal transduction A(FLT1, CDC25B, TBX3,
ADM, VEGF, FGF18)
B(GPSM2, IGFBP5, LRP12,
GNAZ, STK3, MAPRE2,
EXT1, MS4A7, WISP1,
TGFB3, GPR126, NMB,
ADM, NMU, VEGF, FGF18)
1
.000020 .016 lipid metabolic process regulation of cell growth A(CHPT1, DEGS1, RBP3,
ACADS) B(CHPT1, IGFBP5,
WISP1, ESM1)
1
.000000 .016 apoptosis positive regulation of
mitotic cell cycle
A(RAD21, BIRC5) B(BIRC5,
ASNS)
2
.000000 .017 in utero embryonic de-
velopment
negative regulation of
cell proliferation
A(FUT8, TGFB3) B(TGFB3,
BTG2)
2
.000370 .018 nucleosome assembly interspecies interaction
between organisms
A(TSPYL5, CENPA)
B(KRT18, CENPA, SYN-
CRIP, IVNS1ABP)
2
.040590 .023 positive regulation of
cell proliferation
protein amino acid de-
phosphorylation
A(FLT1, CDC25B, TBX3,
ADM, VEGF, FGF18)
B(CDC25B, MTMR2)
1
.000020 .029 metabolic process extracellular matrix or-
ganization and biogene-
sis
A(OXCT1, ALDH4A1, PECI,
MMP9, GSTM3, FLJ12443,
MCCC1, ASNS) B(MMP9,
COL4A2)
1
.000100 .029 proteolysis positive regulation of
apoptosis
A(PITRM1, MMP9, RBP3,
CTSL2, PCSK6) B(MMP9,
STK3, TGFB3, IHPK2)
2
p-val p-val Continued on next page . . . Breast Cancer:1-e
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FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.001440 .030 signal transduction anatomical structure
morphogenesis
A(GPSM2, IGFBP5, LRP12,
GNAZ, STK3, MAPRE2,
EXT1, MS4A7, WISP1,
TGFB3, GPR126, NMB,
ADM, NMU, VEGF, FGF18)
B(KRT18, FGF18)
1
.003490 .031 interspecies interaction
between organisms
anatomical structure
morphogenesis
A(KRT18, CENPA, SYN-
CRIP, IVNS1ABP) B(KRT18,
FGF18)
2
or
3
.000000 .032 in utero embryonic de-
velopment
organ morphogenesis A(FUT8, TGFB3) B(TBX3,
EVL, TGFB3)
1
.000140 .032 skeletal development anti-apoptosis A(MMP9, MATN3, TBX3)
B(BIRC5, TBX3)
1
.008440 .033 positive regulation of
apoptosis
organ morphogenesis A(MMP9, STK3, TGFB3,
IHPK2) B(TBX3, EVL,
TGFB3)
1
.011520 .034 mitosis anti-apoptosis A(CDC25B, RAD21,
MAD2L1, BIRC5, STK6,
MAPRE2, CCNB2, ASPM,
BUB1, FBXO5) B(BIRC5,
TBX3)
1
.028700 .036 metabolic process skeletal development A(OXCT1, ALDH4A1, PECI,
MMP9, GSTM3, FLJ12443,
MCCC1, ASNS) B(MMP9,
MATN3, TBX3)
1
.000000 .037 apoptosis cytokinesis A(RAD21, BIRC5) B(BIRC5,
PRC1)
2
.000130 .040 positive regulation of
cell proliferation
multicellular organis-
mal development
A(FLT1, CDC25B, TBX3,
ADM, VEGF, FGF18)
B(FLT1, KIAA1442, HMGB3,
STMN1, TBX3, VEGF, HRB,
RIP, RPS4X)
1
.000000 .040 positive regulation of
cell proliferation
anatomical structure
morphogenesis
A(FLT1, CDC25B, TBX3,
ADM, VEGF, FGF18)
B(KRT18, FGF18)
1
.006760 .041 cell proliferation nervous system develop-
ment
A(CKS2, MAPRE2, DLG7,
BUB1, VEGF, RPS4X)
B(STMN1, EVL, MYLIP,
VEGF)
1
.000020 .042 negative regulation of
cell proliferation
DNA repair A(TGFB3, BTG2) B(BTG2,
RFC4)
2
.000030 .047 positive regulation of
apoptosis
skeletal development A(MMP9, STK3, TGFB3,
IHPK2) B(MMP9, MATN3,
TBX3)
1
p-val p-val Breast Cancer:1-e
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Table A.3: Breast cancer results for scheme IR 1-1
FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.000000 .000 DNA replication initia-
tion
spindle organization
and biogenesis
A(MCM6, CCNE2) B(CKS2,
STK6, KNTC2)
2
.000010 .000 DNA replication initia-
tion
phosphoinositide-
mediated signaling
A(MCM6, CCNE2) B(CKS2,
STK6, KNTC2, RFC4)
1
.002060 .000 vesicle-mediated trans-
port
transcription from RNA
polymerase II promoter
A(STX1A, RAB6B, AP2B1,
KIAA1181) B(TRIP13, PIR)
1
.017950 .000 intracellular protein
transport
transcription from RNA
polymerase II promoter
A(STX1A, AP2B1, MYRIP)
B(TRIP13, PIR)
2
.000000 .002 nucleosome assembly RNA splicing A(TSPYL5, CENPA)
B(SYNCRIP, IVNS1ABP)
3
.000000 .002 nucleosome assembly interspecies interaction
between organisms
A(TSPYL5, CENPA)
B(KRT18, CENPA, SYN-
CRIP, IVNS1ABP)
2
.000000 .003 G-protein coupled re-
ceptor protein signaling
pathway
endocytosis A(GPSM2, GNAZ) B(LRP12,
TFRC)
2
.004730 .008 transcription transport A(MCM6, KIAA1442, EZH2,
SEC14L2, BTG2) B(RBP3,
SEC14L2, SLC7A1, HRB,
RIP)
3
.000000 .011 female pregnancy protein amino acid
phosphorylation
A(FLT1, ADM) B(FLT1,
STK32B, CDC42BPA, STK6,
STK3, PCTK1, MELK,
BUB1)
1
or
2
.000000 .021 negative regulation of
cell proliferation
DNA repair A(TGFB3, BTG2) B(BTG2,
RFC4)
2
.001940 .023 lipid metabolic process regulation of cell growth A(CHPT1, DEGS1, RBP3,
ACADS) B(CHPT1, IGFBP5,
WISP1, ESM1)
1
.002050 .024 mitosis anti-apoptosis A(CDC25B, RAD21,
MAD2L1, BIRC5, STK6,
MAPRE2, CCNB2, ASPM,
BUB1, FBXO5) B(BIRC5,
TBX3)
1
.000000 .028 proteolysis skeletal development A(PITRM1, MMP9, RBP3,
CTSL2, PCSK6) B(MMP9,
MATN3, TBX3)
2
.000200 .031 cytokinesis anti-apoptosis A(BIRC5, PRC1) B(BIRC5,
TBX3)
2
.005750 .033 regulation of transcrip-
tion, DNA-dependent
negative regulation of
cell proliferation
A(MCM6, KIAA1442, EZH2,
HMGB3, BTG2) B(TGFB3,
BTG2)
1
p-val p-val Continued on next page . . . Breast Cancer:IR1-1
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FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.000880 .035 transcription negative regulation of
cell proliferation
A(MCM6, KIAA1442, EZH2,
SEC14L2, BTG2) B(TGFB3,
BTG2)
1
.000840 .040 cell differentiation female pregnancy A(FLT1, STMN1, HRB, RIP)
B(FLT1, ADM)
1
.027030 .044 skeletal development anti-apoptosis A(MMP9, MATN3, TBX3)
B(BIRC5, TBX3)
1
p-val p-val Breast Cancer:IR1-1
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Table A.4: Breast cancer results for scheme IR 1-e
FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.000000 .000 transcription transport A(MCM6, KIAA1442, EZH2,
SEC14L2, BTG2) B(RBP3,
SEC14L2, SLC7A1, HRB,
RIP)
3
.000240 .003 transcription from RNA
polymerase II promoter
microtubule-based
movement
A(TRIP13, PIR) B(KIF14,
KIF3B, KIF21A)
2
.000000 .007 oxidation reduction endocytosis A(ALDH4A1, ALDH6A1,
DEGS1, QDPR, ACADS, CP)
B(LRP12, TFRC)
2
.000310 .013 nucleosome assembly interspecies interaction
between organisms
A(TSPYL5, CENPA)
B(KRT18, CENPA, SYN-
CRIP, IVNS1ABP)
2
.000000 .016 apoptosis positive regulation of
mitotic cell cycle
A(RAD21, BIRC5) B(BIRC5,
ASNS)
2
.000610 .021 protein amino acid de-
phosphorylation
cell-cell signaling A(CDC25B, MTMR2)
B(DLG7, WISP1, TGFB3,
NMB, ADM, FGF18)
1
.000000 .023 lipid metabolic process regulation of cell growth A(CHPT1, DEGS1, RBP3,
ACADS) B(CHPT1, IGFBP5,
WISP1, ESM1)
1
.001600 .024 mitosis anti-apoptosis A(CDC25B, RAD21,
MAD2L1, BIRC5, STK6,
MAPRE2, CCNB2, ASPM,
BUB1, FBXO5) B(BIRC5,
TBX3)
1
.000130 .024 positive regulation of
cell proliferation
signal transduction A(FLT1, CDC25B, TBX3,
ADM, VEGF, FGF18)
B(GPSM2, IGFBP5, LRP12,
GNAZ, STK3, MAPRE2,
EXT1, MS4A7, WISP1,
TGFB3, GPR126, NMB,
ADM, NMU, VEGF, FGF18)
1
.000410 .024 interspecies interaction
between organisms
anatomical structure
morphogenesis
A(KRT18, CENPA, SYN-
CRIP, IVNS1ABP) B(KRT18,
FGF18)
2
or
3
.000000 .026 regulation of cell growth G-protein coupled re-
ceptor protein signaling
pathway
A(CHPT1, IGFBP5, WISP1,
ESM1) B(GPSM2, GNAZ)
1
p-val p-val Continued on next page . . . Breast Cancer:IR1-e
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FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.000000 .028 signal transduction cell-cell signaling A(GPSM2, IGFBP5, LRP12,
GNAZ, STK3, MAPRE2,
EXT1, MS4A7, WISP1,
TGFB3, GPR126, NMB,
ADM, NMU, VEGF, FGF18)
B(DLG7, WISP1, TGFB3,
NMB, ADM, FGF18)
1
.000040 .029 negative regulation of
cell proliferation
DNA repair A(TGFB3, BTG2) B(BTG2,
RFC4)
2
.000040 .031 positive regulation of
cell proliferation
anatomical structure
morphogenesis
A(FLT1, CDC25B, TBX3,
ADM, VEGF, FGF18)
B(KRT18, FGF18)
1
.000000 .031 positive regulation of
apoptosis
skeletal development A(MMP9, STK3, TGFB3,
IHPK2) B(MMP9, MATN3,
TBX3)
2
.000000 .032 cytokinesis anti-apoptosis A(BIRC5, PRC1) B(BIRC5,
TBX3)
2
.001020 .034 metabolic process skeletal development A(OXCT1, ALDH4A1, PECI,
MMP9, GSTM3, FLJ12443,
MCCC1, ASNS) B(MMP9,
MATN3, TBX3)
1
.035330 .034 skeletal development anti-apoptosis A(MMP9, MATN3, TBX3)
B(BIRC5, TBX3)
1
.000000 .034 protein amino acid de-
phosphorylation
cell proliferation A(CDC25B, MTMR2)
B(CKS2, MAPRE2, DLG7,
BUB1, VEGF, RPS4X)
1
.004060 .036 anatomical structure
morphogenesis
negative regulation of
apoptosis
A(KRT18, FGF18) B(KRT18,
BTG2, VEGF, ASNS)
1
.000070 .037 in utero embryonic de-
velopment
organ morphogenesis A(FUT8, TGFB3) B(TBX3,
EVL, TGFB3)
1
.000000 .041 proteolysis positive regulation of
apoptosis
A(PITRM1, MMP9, RBP3,
CTSL2, PCSK6) B(MMP9,
STK3, TGFB3, IHPK2)
2
.000400 .042 metabolic process extracellular matrix or-
ganization and biogene-
sis
A(OXCT1, ALDH4A1, PECI,
MMP9, GSTM3, FLJ12443,
MCCC1, ASNS) B(MMP9,
COL4A2)
1
.015340 .044 metabolic process positive regulation of
apoptosis
A(OXCT1, ALDH4A1, PECI,
MMP9, GSTM3, FLJ12443,
MCCC1, ASNS) B(MMP9,
STK3, TGFB3, IHPK2)
1
.000000 .045 in utero embryonic de-
velopment
negative regulation of
cell proliferation
A(FUT8, TGFB3) B(TGFB3,
BTG2)
2
p-val p-val Continued on next page . . . Breast Cancer:IR1-e
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.000000 .046 protein amino acid
phosphorylation
cell proliferation A(FLT1, STK32B,
CDC42BPA, STK6, STK3,
PCTK1, MELK, BUB1)
B(CKS2, MAPRE2, DLG7,
BUB1, VEGF, RPS4X)
1
p-val p-val Breast Cancer:IR1-e
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Appendix B: Results for lung cancer data
We also applied our method, presented in chapter 4, on lung cancer dataset (Beer
2002) using the four weighting schemes presented in chapter 5. The results for each
of the four weighting schemes have been summarized in columns. The columns have
been described below.
FDR - FDR p-value:
An association between biological processes is computed using Pearson correlation
coefficient after reducing the gene functions matrices using SVD. These correlation
coefficient values are mapped to the z-values using Fisher exact transformation. These
z-values corresponding to the biological processes annotated with the differentially
expressed genes are compared against the null distribution in the reference built using
Z-test. Corresponding p-values are computed. These p-values are adjusted using False
Discovery Rate (FDR). The adjusted p-values are presented in this column.
Boot - Bootstrap p-value:
We ran bootstrap procedure on our method(s) with 1000 iterations and compute
the p-values. Significant pairs of biological processes are chosen based upon the boot-
strap p-values represented in this column.
Function A:
One of the functions (biological processes in the GO) in the predicted functional
pair.
Function B:
The other function (biological process in the GO) in the predicted functional pair.
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Inputs (A and B)
The input genes that are annotated with function A and function B. The two sets
are grouped separately in parenthesis with letters A or B to identify which functional
category they belong to.
Cat. - Category:
We defined three categories numbered 1 to 3. Each functional pair (association),
after extensive literature review, is assigned to one or more categories. These categories
were defined as, category 1: supported by literature and considered as trivial; category
2: supported by literature and considered non-trivial; and category 3: yet unknown
or the association makes no sense.
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Table B.1: Lung cancer results for scheme 1-1
FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.004989 .008 signal transduction nervous system develop-
ment
A(2886, 11333, 8772, 7422,
7480, 9637, 6198, 5150, 9590,
133, 931, 5026, 1040, 7130,
7436) B(7422, 9637, 3623,
5026, 7436)
1
.029142 .010 interspecies interaction
between organisms
anatomical structure
morphogenesis
A(8772, 3855, 3880, 3875)
B(7471, 3875)
2
or
3
.000896 .014 inflammatory response negative regulation of
cell cycle
A(5970, 650, 7130) B(650,
3623)
2
.000033 .015 regulation of transcrip-
tion from RNA poly-
merase II promoter
intracellular signaling
cascade
A(1398, 1628) B(1398, 3702) 1
.039476 .015 interspecies interaction
between organisms
negative regulation of
apoptosis
A(8772, 3855, 3880, 3875)
B(7422, 3875)
2
.002106 .016 nervous system develop-
ment
ion transport A(7422, 9637, 3623, 5026,
7436) B(5349, 5026)
1
.000009 .022 anti-apoptosis protein modification
process
A(5970, 573) B(7316, 23170,
9870, 573)
1
.000079 .025 cellular defense re-
sponse
protein amino acid
phosphorylation
A(5970, 3702) B(2064, 6198,
3702)
1
.000039 .026 anatomical structure
morphogenesis
cell cycle A(7471, 3875) B(990, 3875) 2
.000034 .026 negative regulation of
apoptosis
anatomical structure
morphogenesis
A(7422, 3875) B(7471, 3875) 1
.000045 .030 blood coagulation organ morphogenesis A(5054, 3673) B(650, 3673) 2
or
3
.028514 .031 protein modification
process
cell surface receptor
linked signal transduc-
tion
A(7316, 23170, 9870, 573)
B(6781, 3623, 573)
1
.000000 .032 intracellular signaling
cascade
cellular defense re-
sponse
A(1398, 3702) B(5970, 3702) 1
.000058 .032 negative regulation of
apoptosis
cell cycle A(7422, 3875) B(990, 3875) 1
.000004 .037 protein transport visual perception A(4666, 5191) B(5191, 1040) 1
.023336 .037 nervous system develop-
ment
induction of apoptosis A(7422, 9637, 3623, 5026,
7436) B(3623, 837)
1
.000076 .038 skeletal development negative regulation of
cell cycle
A(7071, 3623) B(650, 3623) 1
.000048 .043 negative regulation of
cell cycle
organ morphogenesis A(650, 3623) B(650, 3673) 1
p-val p-val Continued on next page . . . Lung Cancer:1-1
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FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.016228 .045 cell proliferation heart development A(11333, 7422, 2064, 5045)
B(2064, 133)
1
.008224 .047 negative regulation of
cell proliferation
skeletal development A(7071, 650, 990) B(7071,
3623)
1
.000257 .048 cell differentiation induction of apoptosis A(7471, 3623, 3267) B(3623,
837)
1
p-val p-val Lung Cancer:1-1
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Table B.2: Lung cancer results for scheme 1-e
FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.000000 .003 proteolysis regulation of cell prolif-
eration
A(7385, 1514, 837) B(1628,
3623)
1
.000000 .005 positive regulation of
cell migration
multicellular organis-
mal development
A(7422, 3912) B(7422, 7480,
7471, 3267)
1
.000010 .005 protein modification
process
regulation of cell prolif-
eration
A(7316, 23170, 9870, 573)
B(1628, 3623)
1
.000000 .009 negative regulation of
cell proliferation
cell cycle A(7071, 650, 990) B(990, 3875) 1
.009430 .010 regulation of transcrip-
tion from RNA poly-
merase II promoter
cell adhesion A(1398, 1628) B(7162, 390,
3673, 3912, 7130)
1
.000000 .010 protein transport visual perception A(4666, 5191) B(5191, 1040) 1
.000000 .010 inflammatory response negative regulation of
cell cycle
A(5970, 650, 7130) B(650,
3623)
2
.000000 .011 cellular defense re-
sponse
protein amino acid
phosphorylation
A(5970, 3702) B(2064, 6198,
3702)
1
.008210 .011 signal transduction lipid transport A(2886, 11333, 8772, 7422,
7480, 9637, 6198, 5150, 9590,
133, 931, 5026, 1040, 7130,
7436) B(10948, 7436)
1
.000000 .012 cell-cell signaling protein modification
process
A(7071, 650, 133, 6781, 3623,
7130) B(7316, 23170, 9870,
573)
1
.000000 .014 signal transduction positive regulation of
cell migration
A(2886, 11333, 8772, 7422,
7480, 9637, 6198, 5150, 9590,
133, 931, 5026, 1040, 7130,
7436) B(7422, 3912)
1
.000000 .014 signal transduction nervous system develop-
ment
A(2886, 11333, 8772, 7422,
7480, 9637, 6198, 5150, 9590,
133, 931, 5026, 1040, 7130,
7436) B(7422, 9637, 3623,
5026, 7436)
1
.009520 .015 signal transduction cholesterol metabolic
process
A(2886, 11333, 8772, 7422,
7480, 9637, 6198, 5150, 9590,
133, 931, 5026, 1040, 7130,
7436) B(10948, 7436)
1
.000000 .015 intracellular signaling
cascade
cellular defense re-
sponse
A(1398, 3702) B(5970, 3702) 1
.000000 .015 protein modification
process
cell surface receptor
linked signal transduc-
tion
A(7316, 23170, 9870, 573)
B(6781, 3623, 573)
1
.000000 .016 positive regulation of
cell migration
nervous system develop-
ment
A(7422, 3912) B(7422, 9637,
3623, 5026, 7436)
1
p-val p-val Continued on next page . . . Lung Cancer:1-e
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FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.000010 .016 protein modification
process
induction of apoptosis A(7316, 23170, 9870, 573)
B(3623, 837)
1
.000000 .016 cell proliferation nervous system develop-
ment
A(11333, 7422, 2064, 5045)
B(7422, 9637, 3623, 5026,
7436)
1
.000000 .017 cell-cell signaling cell surface receptor
linked signal transduc-
tion
A(7071, 650, 133, 6781, 3623,
7130) B(6781, 3623, 573)
1
.048020 .017 regulation of transcrip-
tion from RNA poly-
merase II promoter
protein amino acid
phosphorylation
A(1398, 1628) B(2064, 6198,
3702)
1
.000430 .018 skeletal development protein modification
process
A(7071, 3623) B(7316, 23170,
9870, 573)
1
.000000 .019 anti-apoptosis protein modification
process
A(5970, 573) B(7316, 23170,
9870, 573)
1
.000290 .019 nervous system develop-
ment
cholesterol metabolic
process
A(7422, 9637, 3623, 5026,
7436) B(10948, 7436)
1
.000000 .020 positive regulation of
I-kappaB kinase/NF-
kappaB cascade
transport A(8772, 5970, 6574) B(7385,
7417, 6511, 6574, 3267)
1
.000000 .022 anti-apoptosis cell-cell signaling A(5970, 573) B(7071, 650, 133,
6781, 3623, 7130)
1
.000000 .023 regulation of cell prolif-
eration
induction of apoptosis A(1628, 3623) B(3623, 837) 1
.000320 .025 nervous system develop-
ment
lipid transport A(7422, 9637, 3623, 5026,
7436) B(10948, 7436)
1
.000430 .026 anti-apoptosis skeletal development A(5970, 573) B(7071, 3623) 1
.000000 .026 Wnt receptor signaling
pathway, calcium mod-
ulating pathway
cell differentiation A(7480, 7471) B(7471, 3623,
3267)
2
.000940 .027 regulation of transcrip-
tion from RNA poly-
merase II promoter
intracellular signaling
cascade
A(1398, 1628) B(1398, 3702) 1
.000000 .030 blood coagulation organ morphogenesis A(5054, 3673) B(650, 3673) 2
or
3
.000000 .031 skeletal development induction of apoptosis A(7071, 3623) B(3623, 837) 1
.000000 .032 positive regulation of
cell proliferation
nervous system develop-
ment
A(7422, 5967, 133) B(7422,
9637, 3623, 5026, 7436)
1
.000000 .034 regulation of transcrip-
tion from RNA poly-
merase II promoter
actin cytoskeleton orga-
nization and biogenesis
A(1398, 1628) B(1398, 7114,
390)
1
.000000 .034 nervous system develop-
ment
negative regulation of
apoptosis
A(7422, 9637, 3623, 5026,
7436) B(7422, 3875)
1
.000840 .035 cell proliferation heart development A(11333, 7422, 2064, 5045)
B(2064, 133)
1
p-val p-val Continued on next page . . . Lung Cancer:1-e
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FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.013550 .036 proteolysis negative regulation of
cell cycle
A(7385, 1514, 837) B(650,
3623)
1
or
2
.000000 .041 signal transduction positive regulation of
cell proliferation
A(2886, 11333, 8772, 7422,
7480, 9637, 6198, 5150, 9590,
133, 931, 5026, 1040, 7130,
7436) B(7422, 5967, 133)
1
.003410 .043 interspecies interaction
between organisms
anatomical structure
morphogenesis
A(8772, 3855, 3880, 3875)
B(7471, 3875)
2
or
3
.000000 .046 positive regulation of
I-kappaB kinase/NF-
kappaB cascade
proteolysis A(8772, 5970, 6574) B(7385,
1514, 837)
2
.000010 .047 positive regulation of
cell proliferation
multicellular organis-
mal development
A(7422, 5967, 133) B(7422,
7480, 7471, 3267)
1
.000300 .047 signal transduction negative regulation of
apoptosis
A(2886, 11333, 8772, 7422,
7480, 9637, 6198, 5150, 9590,
133, 931, 5026, 1040, 7130,
7436) B(7422, 3875)
1
.000000 .049 skeletal development negative regulation of
cell cycle
A(7071, 3623) B(650, 3623) 1
.002190 .050 multicellular organis-
mal development
negative regulation of
apoptosis
A(7422, 7480, 7471, 3267)
B(7422, 3875)
1
p-val p-val Lung Cancer:1-e
109
Table B.3: Lung cancer results for scheme IR 1-1
FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.000000 .002 protein transport visual perception A(4666, 5191) B(5191, 1040) 1
.000110 .003 cellular defense re-
sponse
protein modification
process
A(5970, 3702) B(7316, 23170,
9870, 573)
1
.000000 .005 regulation of transcrip-
tion from RNA poly-
merase II promoter
intracellular signaling
cascade
A(1398, 1628) B(1398, 3702) 1
.000000 .006 actin cytoskeleton orga-
nization and biogenesis
regulation of cell prolif-
eration
A(1398, 7114, 390) B(1628,
3623)
1
.000110 .007 signal transduction nervous system develop-
ment
A(2886, 11333, 8772, 7422,
7480, 9637, 6198, 5150, 9590,
133, 931, 5026, 1040, 7130,
7436) B(7422, 9637, 3623,
5026, 7436)
1
.023720 .008 actin cytoskeleton orga-
nization and biogenesis
transcription A(1398, 7114, 390) B(7110,
7071, 1628, 1316, 9689, 4666)
1
.000000 .010 protein modification
process
cell surface receptor
linked signal transduc-
tion
A(7316, 23170, 9870, 573)
B(6781, 3623, 573)
1
.000020 .012 multicellular organis-
mal development
negative regulation of
apoptosis
A(7422, 7480, 7471, 3267)
B(7422, 3875)
1
.002340 .013 inflammatory response negative regulation of
cell cycle
A(5970, 650, 7130) B(650,
3623)
2
.000000 .014 nervous system develop-
ment
ion transport A(7422, 9637, 3623, 5026,
7436) B(5349, 5026)
1
.000000 .020 anti-apoptosis protein modification
process
A(5970, 573) B(7316, 23170,
9870, 573)
1
.000000 .021 regulation of transcrip-
tion from RNA poly-
merase II promoter
actin cytoskeleton orga-
nization and biogenesis
A(1398, 1628) B(1398, 7114,
390)
1
.000000 .022 intracellular signaling
cascade
actin cytoskeleton orga-
nization and biogenesis
A(1398, 3702) B(1398, 7114,
390)
1
.000110 .022 transcription skeletal development A(7110, 7071, 1628, 1316,
9689, 4666) B(7071, 3623)
1
.000000 .022 protein amino acid
phosphorylation
heart development A(2064, 6198, 3702) B(2064,
133)
1
.000000 .024 regulation of cell prolif-
eration
induction of apoptosis A(1628, 3623) B(3623, 837) 1
.000080 .025 transport proteolysis A(7385, 7417, 6511, 6574,
3267) B(7385, 1514, 837)
1
.000000 .026 cellular defense re-
sponse
anti-apoptosis A(5970, 3702) B(5970, 573) 2
.014030 .027 intracellular signaling
cascade
cytoskeleton organiza-
tion and biogenesis
A(1398, 3702) B(3855, 7114) 1
p-val p-val Continued on next page . . . Lung Cancer:IR1-1
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.004390 .028 intracellular signaling
cascade
transcription A(1398, 3702) B(7110, 7071,
1628, 1316, 9689, 4666)
1
.000010 .031 positive regulation of
cell migration
cell adhesion A(7422, 3912) B(7162, 390,
3673, 3912, 7130)
1
.000000 .031 anti-apoptosis inflammatory response A(5970, 573) B(5970, 650,
7130)
1
.005040 .032 regulation of transcrip-
tion, DNA-dependent
anti-apoptosis A(7799, 5970, 7110, 7071,
1316, 9689) B(5970, 573)
1
.001740 .033 cell-cell signaling protein modification
process
A(7071, 650, 133, 6781, 3623,
7130) B(7316, 23170, 9870,
573)
1
.000130 .034 negative regulation of
cell proliferation
skeletal development A(7071, 650, 990) B(7071,
3623)
1
.000000 .035 negative regulation of
cell proliferation
cell cycle A(7071, 650, 990) B(990, 3875) 1
.019050 .038 inflammatory response protein modification
process
A(5970, 650, 7130) B(7316,
23170, 9870, 573)
1
.000770 .040 regulation of transcrip-
tion, DNA-dependent
cellular defense re-
sponse
A(7799, 5970, 7110, 7071,
1316, 9689) B(5970, 3702)
1
.020070 .044 nervous system develop-
ment
cholesterol metabolic
process
A(7422, 9637, 3623, 5026,
7436) B(10948, 7436)
1
.004600 .046 regulation of transcrip-
tion from RNA poly-
merase II promoter
cytoskeleton organiza-
tion and biogenesis
A(1398, 1628) B(3855, 7114) 1
.000000 .049 positive regulation of
cell proliferation
heart development A(7422, 5967, 133) B(2064,
133)
1
p-val p-val Lung Cancer:IR1-1
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Table B.4: Lung cancer results for scheme IR 1-e
FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.001340 .000 regulation of angiogene-
sis
negative regulation of
cell cycle
A(2064, 5054) B(650, 3623) 2
.006900 .000 inflammatory response regulation of angiogene-
sis
A(5970, 650, 7130) B(2064,
5054)
1
.000000 .002 protein transport visual perception A(4666, 5191) B(5191, 1040) 1
.000000 .004 protein modification
process
cell surface receptor
linked signal transduc-
tion
A(7316, 23170, 9870, 573)
B(6781, 3623, 573)
1
.000000 .004 regulation of transcrip-
tion from RNA poly-
merase II promoter
intracellular signaling
cascade
A(1398, 1628) B(1398, 3702) 1
.000000 .005 inflammatory response negative regulation of
cell cycle
A(5970, 650, 7130) B(650,
3623)
2
.000000 .005 regulation of transcrip-
tion from RNA poly-
merase II promoter
protein amino acid
phosphorylation
A(1398, 1628) B(2064, 6198,
3702)
1
.000000 .007 intracellular signaling
cascade
cellular defense re-
sponse
A(1398, 3702) B(5970, 3702) 1
.000000 .008 protein modification
process
induction of apoptosis A(7316, 23170, 9870, 573)
B(3623, 837)
1
.000000 .010 protein modification
process
regulation of cell prolif-
eration
A(7316, 23170, 9870, 573)
B(1628, 3623)
1
.000000 .011 cell-cell signaling protein modification
process
A(7071, 650, 133, 6781, 3623,
7130) B(7316, 23170, 9870,
573)
1
.000000 .015 actin cytoskeleton orga-
nization and biogenesis
cellular defense re-
sponse
A(1398, 7114, 390) B(5970,
3702)
2
.005830 .016 regulation of cell prolif-
eration
lipid transport A(1628, 3623) B(10948, 7436) 1
.000000 .016 cellular defense re-
sponse
protein amino acid
phosphorylation
A(5970, 3702) B(2064, 6198,
3702)
1
.005600 .016 regulation of cell prolif-
eration
cholesterol metabolic
process
A(1628, 3623) B(10948, 7436) 1
.000000 .017 organ morphogenesis cell adhesion A(650, 3673) B(7162, 390,
3673, 3912, 7130)
1
.042120 .017 cholesterol metabolic
process
induction of apoptosis A(10948, 7436) B(3623, 837) 2
.004860 .017 signal transduction lipid transport A(2886, 11333, 8772, 7422,
7480, 9637, 6198, 5150, 9590,
133, 931, 5026, 1040, 7130,
7436) B(10948, 7436)
1
.000000 .018 transcription skeletal development A(7110, 7071, 1628, 1316,
9689, 4666) B(7071, 3623)
1
p-val p-val Continued on next page . . . Lung Cancer:IR1-e
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FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.000000 .019 negative regulation of
cell cycle
cell adhesion A(650, 3623) B(7162, 390,
3673, 3912, 7130)
2
.000000 .019 actin cytoskeleton orga-
nization and biogenesis
protein amino acid
phosphorylation
A(1398, 7114, 390) B(2064,
6198, 3702)
1
.046280 .020 blood coagulation negative regulation of
cell cycle
A(5054, 3673) B(650, 3623) 2
.001160 .021 skeletal development protein modification
process
A(7071, 3623) B(7316, 23170,
9870, 573)
1
.000000 .021 regulation of transcrip-
tion from RNA poly-
merase II promoter
cellular defense re-
sponse
A(1398, 1628) B(5970, 3702) 1
.000000 .022 cell-cell signaling regulation of cell prolif-
eration
A(7071, 650, 133, 6781, 3623,
7130) B(1628, 3623)
1
.000000 .022 positive regulation of
I-kappaB kinase/NF-
kappaB cascade
transport A(8772, 5970, 6574) B(7385,
7417, 6511, 6574, 3267)
1
.000000 .024 positive regulation of
cell migration
nervous system develop-
ment
A(7422, 3912) B(7422, 9637,
3623, 5026, 7436)
1
.000000 .025 nervous system develop-
ment
lipid transport A(7422, 9637, 3623, 5026,
7436) B(10948, 7436)
1
.000000 .025 anti-apoptosis protein modification
process
A(5970, 573) B(7316, 23170,
9870, 573)
1
.012750 .033 signal transduction cholesterol metabolic
process
A(2886, 11333, 8772, 7422,
7480, 9637, 6198, 5150, 9590,
133, 931, 5026, 1040, 7130,
7436) B(10948, 7436)
1
.000000 .033 anti-apoptosis cell-cell signaling A(5970, 573) B(7071, 650, 133,
6781, 3623, 7130)
1
.000000 .034 nervous system develop-
ment
cholesterol metabolic
process
A(7422, 9637, 3623, 5026,
7436) B(10948, 7436)
1
.007150 .034 anti-apoptosis skeletal development A(5970, 573) B(7071, 3623) 1
.000000 .037 cell-cell signaling cell surface receptor
linked signal transduc-
tion
A(7071, 650, 133, 6781, 3623,
7130) B(6781, 3623, 573)
1
.000000 .037 signal transduction nervous system develop-
ment
A(2886, 11333, 8772, 7422,
7480, 9637, 6198, 5150, 9590,
133, 931, 5026, 1040, 7130,
7436) B(7422, 9637, 3623,
5026, 7436)
1
.000000 .038 Wnt receptor signaling
pathway, calcium mod-
ulating pathway
cell differentiation A(7480, 7471) B(7471, 3623,
3267)
2
.000000 .038 inflammatory response organ morphogenesis A(5970, 650, 7130) B(650,
3673)
2
or
3
p-val p-val Continued on next page . . . Lung Cancer:IR1-e
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FDR Boot Function (A) Function (B) Inputs (A and B) Cat.
.000000 .038 regulation of transcrip-
tion, DNA-dependent
skeletal development A(7799, 5970, 7110, 7071,
1316, 9689) B(7071, 3623)
1
.000000 .038 signal transduction positive regulation of
cell proliferation
A(2886, 11333, 8772, 7422,
7480, 9637, 6198, 5150, 9590,
133, 931, 5026, 1040, 7130,
7436) B(7422, 5967, 133)
1
.000000 .039 blood coagulation organ morphogenesis A(5054, 3673) B(650, 3673) 2
or
3
.000000 .040 negative regulation of
cell proliferation
cell cycle A(7071, 650, 990) B(990, 3875) 1
.000180 .041 interspecies interaction
between organisms
negative regulation of
apoptosis
A(8772, 3855, 3880, 3875)
B(7422, 3875)
2
.014200 .042 interspecies interaction
between organisms
anatomical structure
morphogenesis
A(8772, 3855, 3880, 3875)
B(7471, 3875)
2
or
3
.000000 .042 regulation of apoptosis proteolysis A(8772, 837) B(7385, 1514,
837)
1
.000000 .044 negative regulation of
cell cycle
organ morphogenesis A(650, 3623) B(650, 3673) 1
.000010 .046 nervous system develop-
ment
negative regulation of
apoptosis
A(7422, 9637, 3623, 5026,
7436) B(7422, 3875)
1
.000000 .047 inflammatory response cell adhesion A(5970, 650, 7130) B(7162,
390, 3673, 3912, 7130)
1
.000000 .048 cell proliferation nervous system develop-
ment
A(11333, 7422, 2064, 5045)
B(7422, 9637, 3623, 5026,
7436)
1
.038450 .048 signal transduction proteolysis A(2886, 11333, 8772, 7422,
7480, 9637, 6198, 5150, 9590,
133, 931, 5026, 1040, 7130,
7436) B(7385, 1514, 837)
1
.001060 .049 actin cytoskeleton orga-
nization and biogenesis
inflammatory response A(1398, 7114, 390) B(5970,
650, 7130)
2
p-val p-val Lung Cancer:IR1-e
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The development of high throughput technologies such as DNA microarrays has
enabled researchers to measure expression levels on a genomic scale. Correct and effi-
cient biological interpretation of the voluminous data generated by these technologies,
however, remains a challenging problem. A commonly used approach in interpreting
the results of such high throughput experiments is to map the list of differentially
expressed (DE) genes to gene ontology (GO) terms, which provides a list of biolog-
ical processes, biochemical functions, and cellular locations associated with the DE
genes. A previously unexplored aspect is the identifications of unusual associations
between biological processes. Such associations may be signaling biological processes
that interact in a specific way in the condition under study. Here we present a novel
approach that aims at identifying such associations between biological processes that
are significantly different in a given phenotype with respect to the normal. We used
our approach on real data sets involving breast and lung cancer, and predicted as-
sociations among biological processes of the GO ontology that were annotated with
differentially expressed genes. More than 89% of the predicted associations were found
to be correct and valid by an extensive manual review of literature. A subset of such
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interactions was discussed in details and shown to have the potential to open a number
of new avenues for research in lung and breast cancer. These results indicate that the
idea of expanding our interpretation efforts beyond single processes may be useful in
understanding specific experiments.
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